



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 24 FEB 2004

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*Stephen Hendley*

Dated 11 February 2004

Patent Act 1977  
(Rule 16)



09JAN03 E775637-2 000239  
P01/7700 0.00-0300427.2



The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

PC/GW/HSO/P12484GB

2. Patent application number

(The Patent Office will fill in this part)

0300427.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

THE UNIVERSITY OF STRATHCLYDE and THE UNIVERSITY COURT  
McCANCE BUILDING OF THE UNIVERSITY OF  
16 RICHMOND STREET GLASGOW  
GLASGOW. G1 1XQ GILBERT SCOTT BUILDING  
UNITED KINGDOM UNIVERSITY AVENUE  
GLASGOW. G12 8QQ  
UNITED KINGDOM

Patents ADP number (if you know it)

4081667001

If the applicant is a corporate body, give the country/state of its incorporation

773846002

4. Title of the invention

PHARMACEUTICAL COMPOSITION

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

CRUIKSHANK & FAIRWEATHER  
19 ROYAL EXCHANGE SQUARE  
GLASGOW  
G1 3AE

Patents ADP number (if you know it)

547002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

YES

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

116

Claim(s)

Abstract

Drawing(s)

18 + 18

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature *Cruikshank & Fairweather* Date *8/1/03*

CRUIKSHANK & FAIRWEATHER 8 JANUARY 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

DR PAUL CHAPMAN  
0141 221 5767

## Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

Pharmaceutical CompositionField of the Invention

This invention relates in general to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bio-active molecule, as well as methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bio-active molecule.

Background of the Invention

WO 0069887, which is a previous application by the present inventors, relating to protein coated microcrystals. However, there is no specific disclosure of pharmaceutical formulations or other bio-active molecules. The coated crystals disclosed in WO 0069887 are generally coprecipitated from saturated solutions and there is no disclosure that it would be advantageous to use a less than saturated solution.

In WO 00/69887 production of PCMCs by addition of an excess of saturated aqueous solution to solvent is described. The PCMCs described are not suitable for pharmaceutical use. The preferred method in WO 00/69887 for obtaining efficient admixing was to dropwise add the



aqueous solution to an excess of organic miscible solvent with vigorous mixing. However, this batch type process suffers from a number of drawbacks:

5 a) the precipitation conditions are continuously varying because the water content of the solvent is increasing throughout. It has been found that different initial water content leads to different sizes and shapes of crystals;

10 b) the precipitation is carried out into a suspension that contains an increasing quantity of crystals already in suspension. This will enhance the likelihood of nascent crystals fusing onto already formed crystals; and

15 c) if a large-scale batch is required it is difficult to obtain high efficiency agitation with stirred batch reactors without excessive shear forces. High efficiency agitation is generally required to minimise crystal size and prevent cementing of crystals into aggregates. However, high shear forces can initiate  
20 damage to the bioactive molecule such as protein denaturation or nicking of nucleic acids. Alternative approaches to rapid mixing such as nebulising the aqueous inflow to provide very small droplets also have potential problems arising from shear forces and interfacial  
25 denaturation processes.

Taken together, there is a need to develop improved methods for obtaining consistent and reproducible pharmaceutical formulations of the particles on a large scale in order to enable to support clinical trials and manufacture.

The present inventors have now discovered that many of the above problems can be solved using a flow precipitator. This operates by mixing together a continuous stream of the saturated aqueous solution and a continuous stream of the solvent in a small mixing flow chamber similar to those used for creating solvent gradients for HPLC chromatography. The co-precipitation process is initiated in the mixing chamber and the particles then flow out as a suspension in the solvent stream to be collected in a holding vessel. Surprisingly, it is found that the process can be operated for extended periods with no blocking of the inlet tubes as might be expected with such a co-precipitation process. Advantageously, the particles exiting the mixing chamber are found to be highly consistent in size, shape and yield over the whole operating cycle indicating the co-precipitation conditions remain constant. A further advantage is that the flow system can run for many hours unattended and in so doing produce large quantities of particles.

Since the overall system may be sealed and sterilised and each solvent stream can be independently filtered through a sterile filter, the whole process can also be made sterile as required for pharmaceutical formulation manufacture.

### Summary of the Invention

According to a first aspect of the present invention there is provided a pharmaceutical formulation comprising particles wherein the particles comprise:

(a) a substantially non-hygroscopic inner crystalline core comprising molecules with a molecular weight of less than 4kDa and a melting point of above about 90°C; and

(b) an outer coating comprising one or more bio-active molecules

wherein the particles have been formed in a single step by coprecipitating said core forming molecules and said bio-active molecule(s) together.

By substantially non-hygroscopic herein is meant that the crystalline core does not readily take-up and retain moisture. Typically, the particles will not aggregate nor will the core under-go significant changes in morphology or crystallinity on exposure to about 80% relative humidity at room temperature.

By crystalline core is meant that the constituent molecules or ions are organised into a solid 3-dimensional crystal lattice of repeating symmetry that remains substantially unchanged on heating until a well-defined melting transition temperature is reached. Conveniently, the molecules form a crystalline core with a high degree of crystallinity. Typically, a well-defined melting endotherm (i.e. not a glass transition) may be observed on heating the particles in a differential scanning calorimeter (DSC). This is a well-known characteristic showing crystallinity and also shows that the crystalline core may be generally substantially composed of solid-state phases that are thermodynamically stable at room temperature and ambient humidity. The particles according to the present invention may also show birefringence which is also a characteristic of crystallinity. The particles may also shown an X-ray diffraction pattern which is yet again evidence of crystallinity.

By single step is meant that the molecules or ions that provide the crystalline core and the bio-active molecules that provide the outer coating precipitate out of solution together directly in the form of coated particles. i.e. in a one-step procedure. There is therefore no requirement for a separate coating or

milling step. It should also be understood that particle formation does not require any evaporative processes such as occur for example in spray-drying or freeze-drying.

Typically, the coating of bio-active molecules may be substantially continuous. Alternatively, it may be advantageous to have a pharmaceutical formulation comprising particles with a substantially discontinuous coating of bio-active molecules.

The pharmaceutical formulation may comprise particles with a narrow size distribution. Typically, the pharmaceutical formulation may therefore comprise a substantially homogeneous system with a significant number of particles having generally the same or similar size.

The particles may have a maximum cross-sectional dimension of less than about 80 $\mu$ m, preferably less than 50 $\mu$ m across or more preferably less than 20 $\mu$ m. By maximal cross-sectional dimension is meant the largest distance measurable between the diametrically opposite points.

The molecules making up the crystalline core may typically each have a molecular weight less than 2kDa. Preferably, the molecules making up the crystalline core each have a molecular weight of less than 1kDa. More preferably, the molecules making up the crystalline core

each have a molecular weight of less than 500 Daltons. Preferred molecules are those that can be rapidly nucleated to form crystals on undergoing precipitation. Molecules that provide particles that consist substantially of amorphous aggregates or glasses are therefore generally not suitable as core materials.

Typically, the molecules forming the crystalline core have a solubility in water of less than 150 mg/ml and preferably less than 80 mg/ml. Surprisingly, it has been found by the present inventors that molecules with solubilities less than these values tend to produce crystals with improved flow properties. Free-flowing particles are generally preferred for many pharmaceutical manufacturing processes since they, for example, facilitate filling capsules with precise dosages and can be conveniently used for further manipulation such as coating. Free flowing particles are generally of regular size and dimensions, with low static charge. Needle shaped crystals of high aspect ratio are, for example, generally not free flowing and are therefore not preferred in certain formulations.

The molecules which make up the crystalline core may, for example, be: amino acids, zwitterions, peptides, sugars, buffer components, water soluble drugs, organic and inorganic salts, compounds that form strongly

hydrogen bonded lattices or derivatives or any combinations thereof. Typically, the molecules are chosen so as to minimise adverse physiological responses following administration to a recipient.

5       Amino acids suitable for forming the crystalline core may be in the form of pure enantiomers or racemates, Examples include: alanine, arginine, asparagine, glycine, glutamine, histidine, lysine, leucine, isoleucine, norleucine, D-valine, L-valine, mixtures of DL-valine, 10 methionine, phenylalanine, proline and serine or any combination thereof. In particular, L-glutamine, L-histidine, L-serine, L-methionine, L-isoleucine, L-valine or DL-valine are preferred. For amino-acids that have side-chains that substantially ionise under 15 coprecipitation conditions it is preferable to use counterions that generate crystalline salts with low solubility and which are non-hygroscopic. Examples of other molecules and salts for forming the crystalline core may include, but are not limited to  $\alpha$ -lactose,  $\beta$ - 20 lactose, mannitol, ammonium bicarbonate, sodium glutamate, arginine phosphate and betaines.

Typically, the molecules forming the crystalline core have a low solubility in water of, for example, between about 12-150 mg/ml and preferably about 20-80 25 mg/ml at about 25°C. Molecules with a solubility of above

about 150 mg/ml in water may also be used to obtain free flowing particles provided that they are coprecipitated from a sub-saturated aqueous solution. Preferably they are coprecipitated at a concentration of 150 mg/ml or less and more preferably of 80 mg/ml or less. For molecules of high aqueous solubility at 25°C it may also be advantageous to use lower coprecipitation temperatures such as 10°C or 4°C so that they are closer to saturation at concentrations of 150 mg/ml or less. Similarly higher temperatures such as 35°C or 50 °C may be used for coprecipitation of core forming molecules poorly soluble at 25°C. Typically, the molecules forming the crystalline core have a melting point above 120°C and preferably above 150°C. Having a high melting point means that the crystals formed have a high lattice energy and this also increases the degree of crystallinity for the crystalline core.

A typical weight ratio of the solvent:H<sub>2</sub>O:carrier:bio-active agent in a suspension of freshly formed particles may range from about 1000:100:5:3 to about 1000:100:5:0.03. The weight ratio of the solvent:H<sub>2</sub>O may range between about 100:1 to about 4:1.

Conveniently, bio-active molecules forming a coating on the crystalline core may be selected from any molecule



capable of producing a therapeutic effect such as for example an active pharmaceutical ingredient (API). By therapeutic effect is meant any effect which cures, alleviates, removes or lessens the symptoms of, or prevents or reduces the possibility of contracting any disorder or malfunction of the human or animal body and therefore encompasses prophylactic effects.

The coating of bio-active molecules may also comprise excipients commonly used in pharmaceutical formulations such as stabilizers, surfactants, isotonicity modifiers and pH/buffering agents. .

The bio-active molecules may, for example, be: any drug, peptide, polypeptide, protein, nucleic acid, sugar, vaccine component, or any derivative thereof or any combination which produces a therapeutic effect.

Examples of bio-active molecules include, but are not limited to drugs such as: anti-inflammatories, anti-cancer, anti-psychotic, anti-bacterial, anti-fungal; natural or unnatural peptides; proteins such as insulin,  $\alpha 1$  - antitrypsin,  $\alpha$  - chymotrypsin, albumin, interferons, antibodies; nucleic acids such as fragments of genes, DNA from natural sources or synthetic oligonucleotides and anti-sense nucleotides; and sugars such as any mono-, di- or polysaccharides.

Nucleic acids may for example be capable of being expressed once introduced into a recipient. The nucleic acid may thus include appropriate regulatory control elements (e.g. promoters, enhancers, terminators etc) for controlling expression of the nucleic acid. The bio-active molecule may also be a chemically modified derivative of a natural or synthetic therapeutic agent such as a PEG-protein.

The nucleic acid may be comprised within a vector. Any suitable vector known to a man skilled in the art may be used.

Vaccine coating components may, for example, include antigenic components of a disease causing agent, for example a bacterium or virus, such as diptheria toxoid and/or tetanus toxoid. A particular advantage of such vaccine formulations is that they generally show greatly enhanced stability on exposure to high temperature when compared with conventional liquid preparations. Such formulations prepared according to the present invention can, for example, be exposed to temperatures of greater than 45°C for 48 hours and retain their ability to illicit an immune response when tested *in vivo*, whereas standard liquid samples are generally found to be completely inactivated. Vaccines that exhibit high temperature stability do not need to be refrigerated and therefore

provide considerable cost savings in terms of storage and ease of distribution particularly in developing countries. Vaccines are useful for the prevention and/or treatment of infections caused by pathogenic micro-organisms, including viral, fungal, protozoal, amoebic and bacterial infections and the like. Examples of vaccine formulations that can be prepared according to the present invention include sub-unit, attenuated or inactivated organism vaccines including, but not limited to, diphtheria, tetanus, polio, pertussus and hepatitis A, B and C, HIV, rabies and influenza.

Exemplary formulations are comprised of diphtheria taxoid coated DL-valine or L-glutamine crystals. The present inventors have found that samples of diphtheria taxoid coated L-glutamine crystals, for example, may be stored under a range of different conditions and following reconstitution and inoculation may be found to illicit strong primary and secondary immune response in mice. Vaccine coated crystals may be formulated for delivery to a recipient by a number of routes including parenteral, pulmonary and nasal administration. Pulmonary delivery may be particularly efficacious for very young children.

Particles according to the present invention are also applicable to administration of polysaccharides

linked to proteins such as HiB (haemophilis influenza B) and pneumococcal vaccines and live virus vaccines, such as mumps, measles and rubella. Particles according to the present invention may also be prepared with modern flu vaccine components such as MV A vectored influenza vaccine.

In addition vaccine component coated micro-crystals may be useful for formulation of vaccines developed for cancers, especially human cancers, including melanomas; a skin cancer; lung cancer; breast cancer; colon cancer and other cancers. Pulmonary formulations as described herein may be particularly suited for treatment of lung cancer. It should be noted that in addition to protein based vaccines (i.e. protein/peptide components coated on an inner substantially non-hygroscopic crystalline core) nucleic acid based vaccine formulations may also be prepared according to the present invention, wherein nucleic acid molecules are coated on an inner substantially non-hygroscopic crystalline core.

Examples of non-hygroscopic coated particles which have been found to have advantageous properties include those with a crystalline core of DL-valine and a coating of insulin; a crystalline core of L-glycine and a coating of antitrypsin, a crystalline core of Na glutamate and a coating of insulin; a crystalline core of L-methionine

and a coating of insulin; a crystalline core of L-alanine  
and a coating of insulin; a crystalline core of L-valine  
and a coating of insulin; a crystalline core of L-  
histidine and a coating of insulin; a crystalline core of  
5 L-glycine and a coating of  $\alpha$  - antitrypsin; a crystalline  
core of L-glutamine and a coating of albumin: a  
crystalline core of DL-valine and a coating of  
oligonucleotides DQA-HEX; a crystalline core of DL-valine  
and a coating of  $\alpha$ 1-antitrypsin with a further anti-  
10 oxidant outer coating of N-acetyl cystein; a crystalline  
core of DL-valine and a coating of ovalbumin; a  
crystalline core of L-glutamine and a coating of  
ovalbumin, a crystalline core of DL-valine and a coating  
of diptheria taxoid; a crystalline core of L-glutamine  
15 and a coating of diptheria taxoid; a crystalline core of  
DL-valine and a coating of diptheria taxoid; a  
crystalline core of the L-glutamine and a coating of  
tetanus taxoid; a crystalline core of the DL-valine and a  
coating of a mixture of diptheria taxoid and tetanus  
20 taxoid; a crystalline core of L-glutamine and a coating  
of a mixture of diptheria taxoid and tetanus taxoid.

Typically a batch of particles formed under well  
controlled conditions is composed of individual  
microcrystals that all exhibit substantially the same

morphology or crystal-shape and which have a narrow size distribution. This can be conveniently observed in SEM images and verified by particle size measurements. The microcrystals according to the present invention typically have a maximum cross-sectional dimension largest dimension of less than 80 microns. Preferably they have a maximum cross-sectional dimension of less than 40 microns and more preferably less than 20 microns. Particles with a maximum cross-sectional dimension of between 0.5 and 20 micron are most preferred. Alternatively free-flowing powders of spherical aggregates of similar sized microcrystals may be formed with maximum cross-sectional dimension of less than 50 microns and preferably less than 20 microns. A notable aspect of the particles formed with preferred coprecipitants is that their size and morphology remain substantially constant on exposure to high humidities such as up to 80 % RH. In addition their free-flowing characteristics and aerodynamic properties may be retained on re-drying.

The amount of bioactive molecule coated onto each particle can be conveniently varied by changing the ratio of bioactive molecule to core molecule in the initial aqueous solution prior to coprecipitation. Typically the bioactive molecule will make up between 0.1 wt% and 50

wt% of each coated microcrystal. More preferably the loading of bioactive molecule in the particles will be between 1 wt% and 40 wt%.

Typically, at least some of the bio-active molecules retain a high level of activity even after exposure to high humidity.

Typically, the non-hygroscopic coated particles are stable (i.e. substantially retain their bio-activity) on exposure to elevated temperatures and may be stable at up to 60°C for more than 1 week. This aids the storage and shows pharmaceutical formulations formed from the non-hygroscopic coated particles may be expected to have extended shelf-lives even under non-refrigerated conditions.

Typically, the core material of the non-hygroscopic coated particles will absorb less than 5 wt% of water and preferably less than 0.5 wt% at relative humidities of up to 80%. Particles comprising biomolecules will typically absorb higher amounts of water with the wt% depending on the loading

Typically, the bio-active molecules coated on the crystalline core retain a native or near-native configuration i.e. the bio-active molecules are not irreversibly denatured during the production process. Coating of the bioactive molecules onto the crystalline

core is also advantageously found to lead to enhanced stability on storage of the particles at ambient or elevated temperatures. For example, typically the bioactive molecule may retain most of its bioactivity when reconstituted in aqueous media. Preferably the bioactive molecule will retain greater than 50% of its initial bioactivity after storage at 25 C for 6 months. More preferably the bioactive molecule will retain greater than 80% of its bioactivity and most preferably greater than 95% bioactivity.

The fine free-flowing particles or suspensions described typically do not adhere to the walls of a glass vial. The particles typically re-dissolve rapidly and completely in water, aqueous solutions (containing buffers and salts such as those commonly used for reconstitution) or else in physiological fluids. Full redissolution of a dry powder or suspension will generally take place in less than 2 minutes, preferably in less than 60 seconds and most preferably in less than 30 seconds. Formulations reconstituted in aqueous buffer are typically low turbidity, colourless solutions with clarity better than 15 FNU and preferably better than 6 FNU (FNU = Formazine nephelometric units).

Commonly bioactive molecules require excipients or stabilising agents to be present when dissolved in



aqueous solution such as buffer compounds, salts, sugars, surfactants and antioxidants. These may be included in the starting aqueous solution and incorporated into the particles during the coprecipitation process. They will then be present on reconstitution of the particles for example as a pharmaceutical formulation. Typically following coprecipitation of all the components the excipients will be concentrated on the outer surface of the particle and will permeate into the coating of bio-active molecules. A typical antioxidant may, for example, be cysteine such as in the form of N-acetyl cysteine while a typical surfactant may be Tween. During coprecipitation it is possible for the relative ratio of excipients to bioactive molecule to change due to dissolution into the solvent. This may be controlled by pre-addition of selected excipients to either the initial aqueous solution, the coprecipitation solvent or the rinse solvent such that on drying the desired ratio is obtained in the particles. Thus, for example, organic soluble sugars or polymers may be coated onto the surface of protein coated particles by inclusion in the rinse solvent in order to provide enhanced storage stability. Alternatively additives may be included in the rinse solvent and coated onto the outer surface of the particles in order to improve the physical properties of

the particles themselves. For example it is found to be advantageous to provide isoleucine coated insulin-glycine particles by rinsing the formed microcrystals with a solution of isoleucine in 2-propanol prior to drying.

5 These particles have enhanced flow and aerodynamic properties relative to the uncoated ones.

According to a second aspect of the present invention there is provided a method of forming a pharmaceutical formulation comprising particles according

10 to the first aspect comprising the following steps:

(a) preparing an aqueous solution comprising molecules forming a coprecipitant wherein each molecule has a molecular weight of less than 4kDa and a melting point of above about 90°C, and bio-active molecules;

15 (b) rapidly admixing the bio-active molecule/coprecipitant solution with an excess of a substantially water miscible organic solvent such that the coprecipitant and bio-active molecules coprecipitate from solution forming said particles;

20 (c) optionally isolating the particles from the organic solvent; and

thereafter forming a pharmaceutical formulation comprising the particles.

The bioactive molecule may be provided as a solid, for

25 example, as a powder, which is to be dissolved in the

aqueous solution of coprecipitant. Alternatively, the bioactive molecule may be in a solution or suspension prior to mixing with the aqueous solution of coprecipitant. Typically, the coprecipitant may be prepared as a substantially saturated or highly concentrated solution. Following mixing with the bioactive molecule the coprecipitant will typically be at between 5 and 100 % of its aqueous saturation solubility. Preferably it will be between 20 and 80% of its saturation solubility.

The coprecipitant must be sufficiently soluble in the aqueous solution such that a suitable weight fraction may be obtained relative to the bio-active molecule in solution. Preferably, the coprecipitant has a substantially lower solubility in the miscible organic solvent than in the aqueous solution. The concentration of coprecipitant required is a function of the amount of bio-active molecule in the solution and the molecular mass of the bio-active molecule.

The skilled addressee will appreciate that the coprecipitant should be chosen so that it does not substantially react and/or cause an adverse reaction with the bio-active molecule.

The bio-active/coprecipitant solution is admixed with a substantially water miscible organic solvent or

water miscible mixture of solvents, preferably one where the solvent or solvent mixture is substantially fully miscible. Typically, the bio-active molecule /coprecipitant solution is added to an excess of water miscible organic solvent. The excess of fully water miscible organic solvent is such that the final water content of the solvent/aqueous solution is generally less than 30%, typically less than 10-20 vol% and conveniently less than 8 vol%. In this manner, the organic solvent should preferably initially contain less than 0.5-5 vol% water or be substantially dry, but may not necessarily be completely dry.

Typical water miscible organic solvents may, for example, be: methanol; ethanol; propan-1-ol; propan-2-ol; acetone, ethyl lactate, tetrahydrofuran, 2-methyl-2,4-pentanediol, 1,5-pentane diol, and various size polyethylene glycol (PEGS) and polyols; or any combination thereof.

In certain circumstances, the organic solvent may be pre-saturated with the bio-active molecule and/or coprecipitate to ensure that on addition of the aqueous solution the two components precipitate out together.

It should be understood that the term "admixed" refers to a process step wherein the water miscible organic solvent is mixed or agitated with the aqueous

solution while the aqueous solution is added. The mixing needs to be efficient so that the bio-active molecule is in contact with a mixture of intermediate composition i.e. aqueous solution and organic solvent, for example, between 25% and 60% solvent, for a minimal time. It will be appreciated by the skilled reader that admixing therefore does not mean the entire aqueous solution needs to be added to the miscible organic solvent quickly and substantially in a single step and could, for example, be added dropwise. Thus, the aqueous solution may be added to the organic solvent using a wide range of methods such as a continual stream, dropwise or as a spray or mist. Typically the admixing of the bio-active molecule and coprecipitate solution may occur in a process wherein a continuous or dropwise stream of bio-active molecules and coprecipitate are mixed together with an fixed excess amount of solvent in a rapidly stirred batch reactor.

The present inventors have now found that a continuous, as opposed to batch-wise co-precipitation process may also be used which may operate by mixing together two or more continuous streams. Thus a continuous stream of water miscible organic solvent or mixture of solvents may be mixed with a continuous aqueous stream comprising a bio-active molecule/co-precipitant solution in, for example, a small mixing flow

chamber. The water miscible solvent stream may contain water at less than 5 vol% and/or be substantially saturated with coprecipitant to aid coprecipitation. The aqueous stream or solvent stream may also contain other excipients typically employed in pharmaceutical formulations such as buffers, salts and/or surfactants. The co-precipitation process may be initiated in the mixing chamber with the formed particles flowing out as a suspension in the mixed solvent stream to be collected in a holding vessel. The particles exiting the mixing chamber have been found to be substantially consistent in size, shape and yield. Advantageously this continuous process may be carried out over a wide temperature range including temperature between 0 °C and ambient temperature as well as elevated temperatures. Also advantageously the particles may be collected as a suspension in solvent using a holding vessel held at various pressures including atmospheric pressure. Running a continuous process under conditions close to ambient may lead to reduced capital and operating costs relative to conventional methods of forming particles for pharmaceutical applications such as spray-drying or super-critical fluid processing. It is envisaged that large quantities of bio-active molecule coated particles,

for example, may be produced in this manner on an industrial scale.

Alternatively, the bioactive molecule or coprecipitant may be omitted from the aqueous stream and the process used to form uncoated particles. The uncoated particles may for example comprise an excipient or drug useful for pharmaceutical formulation purposes. This can provide a convenient method for producing microcrystals of an excipient or drug in a cost effective process. Excipients or drugs produced in a microcrystalline form may show enhanced properties such as improved flow or compressibility characteristics.

In the continuous co-precipitation system one pump may continuously deliver aqueous solution containing concentrated coprecipitant and bioactive molecule while another pump may deliver a coprecipitant saturated solvent phase. Further pumps may be used if a third component such as a particle coating material is required.

The pumps may be of many different kinds but must accurately deliver the solutions at a defined flow rate and be compatible with the bioactive molecules employed. Conveniently, HPLC pumps or the like can be used since these are optimised for delivering aqueous solutions and water miscible solvents over a range of flow rates.

Typically, the aqueous solution will be delivered at flow rates between 0.1 ml/min and 20 ml/min. The aqueous pump head and lines may be made of material that resists fouling by the bioactive molecule. The solvent may generally be delivered 4-100 times faster than the aqueous and so a more powerful/efficient pump may be required. Typically the solvent may be delivered at between 2 ml/min and 200 ml/min.

A mixing device may provide a method for rapidly and intimately admixing a continuous aqueous stream with a continuous water miscible solvent stream such that precipitation begins to occur almost immediately.

The mixing device may be any device that achieves rapid mixing of the two flows. Thus it can, for example, be a static device that operates by shaping/combining the incoming liquid flow patterns or else a dynamic device that actively agitates the two fluid streams together. Preferably, it is a dynamic device. Agitation of the two streams may be achieved by use of a variety of means such as stirring, sonication, shaking or the like. Methods of stirring include a paddle stirrer, a screw and a magnetic stirrer. If magnetic stirring is used a variety of stirring bars can be used with different profiles such as, for example, a simple rod or a Maltese cross. The material lining the interior of the mixing device may



preferably be chosen to prevent significant binding of the bioactive molecule or the particles onto it. Suitable materials may include 316 stainless steel, titanium, silicone and Teflon (Registered Trade Mark).

5            Depending on the production scale required the mixing device may be produced in different sizes and geometries. The size of the mixing chamber required is a function of the rate of flow of the two solvent streams. For flow rates of about 0.025 - 2 ml/min of aqueous and  
10           2.5-20 ml/min of solvent it is convenient to use a 0.2 ml mixing chamber.

            Typically, in either a batch or continuous process the bio-active/coprecipitate solution is added to an excess of water miscible organic solvent. This entails  
15           the smaller volume of bio-active molecule/coprecipitate solution being added to the larger volume of the excess of organic solvent such that rapid dilution of water from the bio-active molecule/coprecipitate solution into the organic solvent occurs with an accompanying rapid  
20           dehydration of the bio-active molecule and formation of particles according to the first aspect. The temperature at which the precipitation is carried out may be varied. For example, the aqueous solution and the solvent may be either heated or cooled. Cooling may be useful where the  
25           bio-active molecule is fragile. Alternatively, the

solvent and aqueous mixtures may be at different temperatures. For example, the solvent may be held at a temperature below the freezing point of the aqueous mixture. Moreover, the pressure may also be varied, for example, higher pressures may be useful to reduce the volatility of the solvent.

Upon admixing the bio-active molecule/coprecipitant solution to the excess of the water miscible organic solvent, precipitation of the bio-active and coprecipitant occurs substantially instantaneously.

Typically, the precipitated particles may be further dehydrated by rinsing with fresh organic solvent containing low amounts of water. This may also be useful to remove residual solvent saturated in coprecipitant. On drying this residual coprecipitant may otherwise serve to cement particles together leading to the formation of aggregates. Rinsing with solutions of excipients prior to drying or storage may also be used to introduce other excipients onto the particles.

It has advantageously been found that the precipitated particles may be stored in an organic solvent and that the bio-active molecules display extremely good retention of activity and stability over an extended period of time. Moreover, precipitated bio-active molecules stored in an organic solvent, will

typically be resistant to attack by bacteria, thus increasing their storage lifetime.

With time the coprecipitate will settle, which allows easy recovery of a concentrated suspension of particles by decanting off excess solvent. The coprecipitate may, however, be subjected to, for example, centrifugation and/or filtration in order to more rapidly recover the precipitated particles. Conventional drying procedures known in the art such as air drying, vacuum drying or fluidised bed drying may be used to evaporate any residual solvent to leave solvent free particles.

Alternatively, solvent may be removed from the particles in a drying procedure using supercritical CO<sub>2</sub>. Typically, particles in a solvent prepared according to the second aspect using a batch-type process or a continuous process, and also non-pharmaceutical particles in a solvent prepared as defined in WO 0069887 may be loaded into a high pressure chamber with supercritical fluid CO<sub>2</sub> flowing through the suspension until the solvent (or as much as possible) has been removed. This technique removes virtually all residual solvent from the particles. This is of particular benefit for pharmaceutical formulation since residual solvent may lead to unexpected physiological effects. A further advantage of super-critical fluid drying of the

suspensions is that it can be used to produce powders and pharmaceutical formulations with much lower bulk density than obtained by other isolation techniques. Typically bulk densities lower than 0.75 g/ml may be obtained.

5 Low bulk density formulations are particularly useful for pulmonary delivery of bio-active molecules since they generally contain fewer strongly bound aggregates. The critical point drying may be carried out in a number of different ways known in the art.

10 It is therefore possible to set up a continuous co-precipitation system to form particles according to the first aspect and, in fact, any other type of particles and then dry the particles using supercritical CO<sub>2</sub>.

15 For pharmaceutical applications dry precipitated particles may be typically introduced into a sterile delivery device or vial under sterile conditions prior to use. Alternatively the particles may be transferred into the sterile delivery device or vial as a suspension in solvent under sterile conditions. They may then be  
20 optionally dried in situ using for example supercritical CO<sub>2</sub> drying.

The methods described herein may also allow organic soluble components present in the aqueous solution to be separated from the bio-active molecules. For example, a  
25 buffer such as Tris which in its free base form is

soluble in an organic solvent like ethanol may be separated from the bio-active molecule during precipitation. However, it may be necessary to convert all the buffer to the free base by the addition of another organic soluble base to the aqueous solution or organic solvent. Thus the present invention also discloses a method of removing undesirable components from the bio-active molecule such that the undesirable components are not co-precipitated with the bio-active molecule and so remain dissolved in the organic phase. This may be achieved by the inclusion of additives such as acids, bases, ion-pairing and chelating agents in aqueous or organic solvent prior to bio-active molecule precipitation of the non-hygroscopic coated particles. The bio-active molecules may therefore be coated in a highly pure form.

The formulations described in the first aspect of the invention may typically be produced by the second aspect of the invention at a number of dosage strengths. The dosage may be conveniently varied by varying the percentage weight of bio-active molecule per particle from below 0.1 wt% up to about 50 wt%. For bio-active molecules that have low solubility in aqueous solution or else are unstable at high aqueous concentrations, it is advantageous to use carriers that form saturated aqueous

solutions at low concentrations. This then allows high loadings to be achieved using low concentrations of the bio-active molecule. The carrier solubility may provide the possibility of producing particles that contain bio-active molecules at loadings from 50 wt% to <0.1 wt% so that the dosage strength of the pharmaceutical formulation can be conveniently varied. The carrier solubility in aqueous solution at room temperature may range from 2-200 mg/ml and more preferable in the range 10-150 mg/ml.

The use of carrier dissolved at concentrations lower than 80 mg/ml can advantageously be used to produce pharmaceutical formulations containing free-flowing particles that span a narrow size distribution with a mean particle size of less than 50 microns. Formulations containing a narrow size distribution of coated crystals provide improved delivery reproducibility and hence better clinical performance.

The pharmaceutical formulations described can be conveniently produced in a sterile form by pre-filtering the aqueous and organic solutions through 0.2 micron filters prior to admixing them in a contained sterile environment. Pharmaceutical formulations should be substantially free of harmful residual solvents and this invention typically provides powders containing less than

0.5 wt% of a Class 3 solvent following conventional drying procedures. Substantially lower solvent levels are obtainable by flowing supercritical fluid CO<sub>2</sub> through a suspension of the crystals in a dry water miscible and CO<sub>2</sub> miscible solvent.

According to a third aspect of the present invention there is provided a pharmaceutical formulation for pulmonary delivery comprising particles according to the first aspect.

In order to use inhalation to administer drug molecules into the bloodstream, the drug must be made into a formulation capable of being delivered to the deep lung. In the case of dry-powder, this generally requires particles with mass median dimensions in the range 1-5 microns, although it has been demonstrated that larger particles with special aerodynamic properties may be used. Certain formulations of particles according to the present invention are suitable for forming pulmonary formulations as they can be used to generate fine free-flowing particles well suited to delivery by inhalation. Given that the bio-active molecule is on the surface of these non-hygroscopic coated particles, the particles generally exhibit unexpectedly low static charge and are straight-forward to handle and use in a delivery device

as a dry powder. Alternatively, for example, they can be used as a suspension in a nebulisor.

In particular, bio-active molecules suitable for the formation of pulmonary pharmaceutical formulations may include but are not restricted to any of the following: therapeutic proteins such as insulin,  $\alpha$ 1-antitrypsin, interferons; antibodies and antibody fragments and derivatives; therapeutic peptides and hormones; synthetic and natural DNA including DNA based medicines; enzymes; vaccine components; antibiotics; pain-killers; water-soluble drugs; water-sensitive drugs; lipids and surfactants; polysaccharides; or any combination or derivatives thereof. The pulmonary formulation comprising particles may be used directly in an inhaler device to provide high emitted doses and high fine particle fractions. Thus emitted doses measured in a MSLI (stages 1-5) are typically greater than 70%. The fine particle fractions measured in a MSLI (stages 3-5) are typically greater than 20% and preferably greater than 30%. The fine particle fraction is defined as the fraction collected on the lower stages of a multi-stage liquid impinger (MSLI) and corresponds to particles with aerodynamic properties suitable for administration to the deep lung by inhalation ie less than about 3.3 microns. The pulmonary formulation may be used in a dry powder



delivery device without any further formulation with, for example, larger carrier particles such as lactose.

For pulmonary formulations, particles with a mass median aerodynamic diameter less than 10 microns and more preferably less than 5 microns are preferred. These will typically have a mass median diameter similar to their mass median aerodynamic diameter. Typically free-flowing, non-hygroscopic low static particles with maximum cross-sectional diameters in the range of 1-5 microns are preferred. These can be obtained using amino-acids such as for example, L-glutamine to form the crystalline core. However, the inventors have surprisingly discovered that bio-active molecule coated particles that take the form of high aspect ratio flakes may advantageously have mass median aerodynamic diameters smaller than their maximum cross-sectional diameters. Suitable shapes may be, for example, leaf shaped or tile shaped. With such particles the preferred range of maximum cross-sectional diameters may be greater than 1-5 microns and may for example be 1-10 microns. Coprecipitants which typically form bioactive molecule coated crystalline particles of this shape include histidine, and D,L-valine. For dry powder pulmonary formulations, particles made with coprecipitants that produce high aspect ratio flakes are therefore also preferred.

In particular, pulmonary formulations may preferably be selected to have crystalline cores comprised of amino-acids such as valine, histidine, isoleucine, glycine or glutamine and which, for example, include: a crystalline core of valine and a coating of a therapeutic protein such as insulin; a crystalline core of histidine and a coating of an enzyme; a crystalline core of valine and a coating of an enzyme inhibitor such as  $\alpha$ -antitrypsin; a crystalline core of valine and a coating of DNA; a crystalline core of valine and a vaccine coating; a crystalline core of glutamine and a vaccine coating; a crystalline core of glutamine and a coating of albumin. It is preferred when forming the particles for the formulation that co-precipitants are used which give discrete particles which do not aggregate on exposure to high humidity. In addition it is preferable that the coprecipitant does not leave an unpleasant taste in the patients mouth following administration. Glutamine is therefore highly preferred since it can be exposed to high humidity and has a bland taste.

According to a fourth aspect of the present invention there is provided a parenteral formulation comprising particles or suspensions of particles according to the first aspect. Such formulations may be delivered by a variety of methods including intravenous,

subcutaneous or intra-muscular injection or else may be used in sustained or controlled release formulations. The particles may be advantageously produced in a cost effective process to provide sterile parenteral formulations that exhibit extended shelf-life at ambient temperatures. Formulations in the form of powders or suspensions may be preferably reconstituted in aqueous solution in less than 60 seconds to provide low turbidity solutions suitable for injection. Reconstitution of suspensions may be preferred where the bioactive molecule is particularly toxic or potent and therefore difficult to manufacture or handle as a dry powder. Alternatively concentrated suspensions of particles in a solvent such as, for example, ethanol may be used for direct parenteral administration without reconstitution. This may provide advantages for bioactive molecules that require to be delivered at very high dosage forms to provide therapeutic effectiveness. Such bioactive molecules may include therapeutic antibodies and derivatives thereof. These may undergo aggregation on reconstitution or else may form highly viscous solutions that are difficult to administer. Concentrated suspensions of particles containing a high dosage of bioactive molecule may therefore be used to provide an alternative more convenient and therapeutically effective

way of delivering such molecules. Bioactive molecule coated particles are particularly suited to this application because they reconstitute very rapidly and show minimal aggregation of the bioactive molecule.

5 Administration of aggregates is undesirable because it may lead to initiation of an adverse immune response.

Bioactive molecules suitable for administration by parenteral delivery include those described in the third aspect of this invention. In addition parenteral

10 administration can be used to deliver larger biomolecules such as vaccines or antibodies not suited to administration into the subject's blood-stream via the lung because of poor systemic bioavailability. Preferred crystalline core materials include excipients commonly

15 used in parenteral formulations such as mannitol and sucrose. Also preferred are natural amino-acids such as L-glutamine that can be used to form particles that reconstitute rapidly, are stable even at high temperature and are easy to process and handle. L-glutamine is also

20 preferred because it has been administered to patients at high dosages with no adverse side-effects.

According to a fifth aspect of the present invention there is provided a sustained or controlled release pharmaceutical formulation (or a depots) comprising

25 particles or suspensions of particles according to the

first aspect. For certain applications it is preferable to produce parenteral or pulmonary formulations or other formulations that on administration provide sustained or extended therapeutic effects. This may, for example, be used to limit the maximum concentration of bioactive molecule that is attained in the subject's bloodstream or else be used to extend the period required between repeat administrations. Alternatively it may be necessary to change the surface characteristic of the particles to improve their bioavailability. The bioactive molecule coated particles can be conveniently used to produce sustained or controlled release formulations. This can be achieved by coating the particles or incorporating them in another matrix material such as a gel or polymer or by immobilising them within a delivery device.

For example each of the particles may be evenly coated with a material which alters the release or delivery of the components of the particles using techniques known in the art.

Materials which may be used to coat the particles may, for example, be: poorly water-soluble biodegradable polymers such as, for example, polylactide or polyglycolide and copolymers thereof; polyamino-acids; hydrogels; and other materials known in the art that change their solubility or degree of cross-linking in

response to exposure to physiological conditions. The coating may for example be applied by contacting a suspension of particles with a solution of the coating material and then drying the resulting particles. If  
5 required the process can be repeated to extend the release profile. The coated particles may be found to provide a substantially constant rate of release of the bioactive molecule into solution. Alternatively, a plurality of the particles may be combined into, for  
10 example, a single tablet form by, for example, by a binding agent. The binding agent may dissolve in solution whereupon the particles may be continually released into solution as the binding agent holding the tablet together progressively dissolves.

15 Those skilled in the art will realise that using combinations of the above teaching it is possible to provide other pharmaceutical formulations such as for example nasal formulations, oral formulations and topical formulations. Nasal formulations and oral formulations  
20 may require coating of the particles with alternate materials that provide adhesion to for example mucosal membranes.

According to a sixth aspect of the present invention there is provided a pulmonary drug delivery device  
25 comprising particles according to the first aspect.

The pulmonary drug delivery device may, for example, be a liquid nebulizer, aerosol-based metered dose inhaler or dry powder dispersion device.

5     Brief Description of the Drawings

Embodiments of the present invention will now be described, by way of example, with reference to the accompanying drawings in which:

10     Figure 1 is a representation of the particle size distribution for insulin/glycine precipitated in propan-2-ol;

Figure 2 is a representation of the particle size distribution for  $\alpha$ -chymotrypsin/L-alanine precipitated in propan-2-ol;

15     Figure 3 is a representation of the particle size distribution for  $\alpha$ -chymotrypsin/DL-valine precipitated in propan-2-ol;

Figure 4 is a representation of the particle size distribution for DL-valine precipitated in propan-2-ol;

20     Figure 5 is a representation of the particle size distribution for insulin/L-histidine precipitated in propan-2-ol;

Figure 6 is a representation of the particle size distribution for DL-valine precipitated in propan-2-ol;

25     Figure 7 is a representation of the particle size distribution for L-glutamine precipitated in propan-2-ol;

Figure 8 is a representation of the particle size distribution for L-glutamine precipitated in propan-2-ol;

Figure 9 is a representation of the particle size distribution for albumin/L-glutamine precipitated in propan-2-ol;

Figure 10 is a Differential Vapour Sorption (DVS) graph of L-glutamine;

Figure 11 is a DVS graph of L- glycine;

Figure 12 is a DVS graph of L-glycine/insulin PCMCs;

Figure 13 is a DVS graph of DL-valine/insulin PCMCs;

Figure 14 is a DVS graph of DL-valine;

Figure 15 is a DVS graph of albumin/L-glutamine;

Figure 16 is a representation of a continuous flow precipitation apparatus;

Figure 17 shows the distribution of DQA-HEX and crude oligonucleotide/DL-valine in an artificial lung;

Figure 18 shows the bioactive response afforded by insulin/DL-valine particles similar to that of USP insulin;

Figure 19 is a representation of wire myograph studies showing again bioactive response afforded by insulin/DL-valine particles similar to that of USP insulin;

Figure 20 is an SEM image of insulin/DL-valine PCMCs;

Figure 21 is an SEM image of insulin/DL-valine PCMCs;



Figure 22 is an SEM image of albumin/L-glutamine PCMCs;

Figure 23 is an SEM image of insulin/L-histidine PCMCs; and

5 Figure 24 is an SEM image of  $\alpha$ -antitrypsin/DL-valine PCMCs.

(It should be noted that although in the following examples the coated particles are referred to as PCMCs, 10 the particles need not necessarily be coated with a protein and may have any bio-active coating)

### Example Section

#### 15 Example 1

Table 1 shows the conditions used to produce a range of protein coated microcrystals (PCMCs) wherein the bio-active material which forms a coating is insulin and the crystalline core is formed from DL-valine, L-valine, L-histidine and L-glycine. The microcrystals were made 20 according to the entry under Crystallisation Process in glass vials or flasks and mixing was carried out by magnetic stirring.

Insulin used is bovine pancreas insulin (Sigma 25 I5500) and USP bovine insulin (Sigma I8405).

Crystals were isolated by filtering through Durapore membrane filters (0.4 microns) and were then dried in air in a fume hood.

5 Protein loadings were determined using Biorad Protein Assay. Percentage of Fine Particle Fraction (FPF) was determined using a Mastersizer 2000 (see later).

Table 1

Bioactive Molecule	Bioactive Molecule dissolved in Solvent	Solvent/ H <sub>2</sub> O% (v/v)	Conc. of Bioactive Molecule in Solvent (mg/ml)	Addition of excipient	Wash Step	Crystallisation Process	% protein recovered	% protein in crystal	% FPF
80mg Insulin (I5500)	8ml of 0.01M HCl and then 400µl of 1M NaOH added	Propan-2-ol 9.1% H <sub>2</sub> O	0.44	8ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.6 and a 49% saturation of DL-valine	None	14ml of insulin in DL-valine added dropwise to 140 ml of propan-2-ol with constant agitation at room temp	-	18	40.0
10mg Insulin (I5500)	1ml of 0.01M HCl and then 50µl of 1M NaOH added	Propan-2-ol 4.8% H <sub>2</sub> O	0.23	1ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.68 and a 49% saturation of DL-valine	None	1.75ml of insulin in DL-valine added dropwise to 35 ml of propan-2-ol with constant agitation at room temp	-	14	32.1
20mg Insulin (I5500)	2ml of 0.01M HCl and then 100µl of 1M NaOH added	Propan-1-ol 9.1% H <sub>2</sub> O	0.44	2ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.61 and a 49% saturation of DL-valine	None	3.5ml of insulin in DL-valine added dropwise to 35 ml of propan-1-ol with constant agitation at room temp	-	33	32.0
20mg Insulin (I5500)	2ml of 0.01M HCl and then 100µl of 1M NaOH added	Ethanol 9.1% H <sub>2</sub> O	0.44	2ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.65 and a 49% saturation of DL-valine	None	3.5ml of insulin in DL-valine added dropwise to 35 ml of ethanol with constant agitation at room temp	-	18	27.0

20mg Insulin (15500)	2ml of 0.01M HCl and then 100µl of 1M NaOH added	Propan-2-ol 9.01% H <sub>2</sub> O	0.44	2ml of distilled water saturated with DL-valine and 0.41ml of dry propan-2-ol added to insulin giving 44% saturation of DL-valine (9.1% v/v propan-2-ol in the aqueous phase	Propan-2-ol (9.1% H <sub>2</sub> O v/v)	3.85ml of insulin in DL-valine added dropwise to 35 ml of propan-2-ol with constant agitation at room temp	-	20	31.0
20mg Insulin (15500)	2ml of 0.01M HCl and then 100µl of 1M NaOH added	Propan-2-ol 9.01% H <sub>2</sub> O	0.44	2ml of distilled water saturated with DL-valine and 0.82ml of dry propan-2-ol added to insulin giving 41% saturation of DL-valine (17% v/v propan-2-ol in the aqueous phase	Propan-2-ol (8.9% H <sub>2</sub> O v/v)	4.2ml of insulin in DL-valine added dropwise to 35 ml of propan-2-ol with constant agitation* at room temp	-	23	49.7
20mg Insulin (USP)	2ml of 0.01M HCl and then 100µl of 1M NaOH added	Propan-2-ol 9.1% H <sub>2</sub> O	0.44	2ml of distilled water saturated with L-valine added to insulin giving a final pH of 8.61 and a 49% saturation of L-valine	None	3.5ml of insulin in L-valine added dropwise to 35 ml of propan-2-ol with constant agitation at room temp	-	18	23.0
80mg Insulin (USP)	8ml of 0.01M HCl and then 400µl of 1M NaOH added	Propan-2-ol 9.1% H <sub>2</sub> O	0.44	8ml of distilled water saturated with L-histidine added to insulin giving a final pH of 8.5 and a 49% saturation of L-histidine	None	14ml of insulin in L-histidine added dropwise to 140 ml of propan-2-ol with constant agitation at room temp	-	27.6	30.2

10mg Insulin (15500)	1ml of 0.01MHCl and then 50ul of 1M NaOH added	Propan-2-ol 4.8% H <sub>2</sub> O	0.23	1ml of distilled water saturated with L- glycine added to insulin giving a final pH of 8.08 and a 49% saturation of L- glycine	Propan-2-ol saturated with isoleucine	1.75ml of insulin in L- glycine added dropwise to 35 ml of propan-2-ol with constant agitation at room temp	-	4.1	27.6
----------------------------	---	--------------------------------------	------	--	--	---	---	-----	------

Table 1 demonstrates that insulin coated particles with free-flowing physical properties suitable for pharmaceutical formulations can be made with a range of different coprecipitants. The coprecipitations were all carried out at concentrations of excipient below 80 mg/ml except for the last entry. In the latter case a modified rinsing procedure was used to further coat the crystals with isoleucine. The consistently high fine particle fractions (FPF) and emitted dose (not shown) illustrate the free flowing nature of the particles and demonstrates that a significant proportion have an effective aerodynamic dimension below 3 microns. It is also clear from Table 1 that it is possible to change process conditions to alter the loading of insulin and the physical properties of the particles.

#### Example 2

Table 2 shows a range of further insulin coated PCMCs made as in Example 1 wherein the crystalline core is formed from L-glycine, L-alanine and L-arginine.

Insulin used is bovine pancreas insulin (Sigma I5500) and USP bovine insulin (Sigma I8405).

Table 2

Bioactive Molecule	Bioactive Molecule dissolved in Solvent	Solvent/ H <sub>2</sub> O% (v/v)	Conc. of Bioactive Molecule in Solvent (mg/ml)	Addition of excipient	Wash Step	Crystallisation Process	% protein recovered	% protein in crystal	% FPF
20mg Insulin (15500)	2ml of 0.01MHCl and then 100µl of 1M NaOH added	Propan-2-ol 9.1% H <sub>2</sub> O	0.44	2ml of distilled water saturated with L-glycine added to insulin giving a final pH of 8.66 and a 49% saturation of L-glycine	None	3.5ml of insulin in L-glycine added dropwise to 35 ml of propan-2-ol with constant agitation at room temp	-	5.4	7.2
80mg Insulin (15500)	8ml of 0.01MHCl and then 400µl of 1M NaOH added	Propan-2-ol 9.1% H <sub>2</sub> O	0.44	8ml of distilled water saturated with L-alanine added to insulin giving a final pH of 8.26 and a 49% saturation of L-alanine	None	14ml of insulin in L-alanine added dropwise to 140 ml of propan-2-ol with constant agitation at room temp	-	7.0	10.5
20mg Insulin (USP)	2ml of 0.01MHCl and then 100µl of 1M NaOH added	Propan-2-ol 9.1% H <sub>2</sub> O	0.44	2ml of distilled water saturated with L-arginine added to insulin giving a final pH>10 and a 49% saturation of L-arginine	None	3.5ml of insulin in L-arginine added dropwise to 35 ml of propan-2-ol with constant agitation at room temp	-	1.3	1.1

Table 2 shows that particles produced from coprecipitants with high solubilities have inferior properties in the MSLI. Particle size measurements described below also show the presence of large aggregates of individual crystals. Another point illustrated is that particles with high loadings of the bioactive molecule (insulin) cannot be obtained when such high solubility compounds are used at close to saturation. In order to produce particles useful for pharmaceutical formulations it is therefore preferable to use lower solubility coprecipitants and/or to amend the process described in WO 0069887 by using sub-saturated solutions

### Example 3

Table 3 shows a range of insulin PCMCs with a crystalline core of DL-valine. The water miscible solvent used is propan-2-ol. The microcrystals were made according to the method of Example 1.



Table 3

Bioactive Molecule	Bioactive Molecule dissolved in Solvent	H <sub>2</sub> O% (v/v)	Conc. of Bioactive Molecule in Solvent (mg/ml)	Addition of excipient	Wash Step	Crystallisation Process	% protein recovered	% max protein in crystal
4mg Insulin (I5500)	6.4ml of 0.01M HCl and then 320µl of 1M NaOH added	9.1	0.028	6.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	1.3
4mg Insulin (I5500)	3.2ml of 0.01M HCl and then 160µl of 1M NaOH added	9.1	0.055	3.2ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	2.6
4mg Insulin (I5500)	1.6ml of 0.01M HCl and then 80µl of 1M NaOH added	9.1	0.11	1.6ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	5.1
4mg Insulin (I5500)	0.8ml of 0.01M HCl and then 40µl of 1M NaOH added	9.1	0.22	0.8ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	9.5
4mg Insulin (I5500)	0.4ml of 0.01M HCl and then 20µl of 1M NaOH added	9.1	0.44	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	18
6mg Insulin (I5500)	0.4ml of 0.01M HCl and then 20µl of 1M NaOH added	9.1	0.67	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	24

It is therefore straightforward to alter the percentage of protein within the particles in order to provide pharmaceutical formulations with different dosage strengths.

5

Example 4

Table 4 shows a series of further insulin coated PCMCs with a crystalline core of DL-valine. The microcrystals were made according to Example 1.

Table 4

Bioactive Molecule	Bioactive Molecule dissolved in Solvent	H <sub>2</sub> O% (v/v)	Conc. of Bioactive Molecule in Solvent (mg/ml)	Addition of excipient	Wash Step	Crystallisation Process	% protein recovered	% max protein in crystal
4mg USP Insulin (18405)	0.4ml of 0.01MHCl and then 20µl of 1M NaOH added	9.1	0.44	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	17
8mg USP Insulin (18405)	0.4ml of 0.01MHCl and then 20µl of 1M NaOH added	9.1	0.89	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	29
4mg USP Insulin (18405)	0.4ml of 0.01MHCl and then 20µl of 1M NaOH added	9.1	0.44	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	17
8mg USP Insulin (18405)	0.4ml of 0.01MHCl and then 20µl of 1M NaOH added	9.1	0.89	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	29
4mg USP Insulin (18405)	0.4ml of 0.01MHCl and then 20µl of 1M NaOH added	9.1	0.44	0.4ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan-2-ol	0.7ml of insulin in DL-valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	-	16
8mg USP	0.4ml of	9.1	0.89	0.4ml of distilled water	Dry	0.7ml of insulin in DL-	-	30

Insulin (18405)	0.01MHCl and then 20µl of 1M NaOH added			saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	propan- 2-ol	valine added dropwise (0.1ml/min) to 7ml of propan-2-ol with constant agitation at room temp	
20mg USP Insulin (18405)	2ml of 0.01MHCl and then 100µl of 1M NaOH added	9.1	0.44	2ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan- 2-ol	3.5ml of insulin in DL- valine added dropwise to 35ml of propan-2-ol with constant agitation at room temp	17
20mg USP Insulin (18405)	2ml of 0.01MHCl and then 100µl of 1M NaOH added	9.1	0.44	2ml of distilled water saturated with DL-valine added to insulin giving a final pH of 8.8 and a 49% saturation of DL-valine	Dry propan- 2-ol	3.5ml of insulin in DL- valine added dropwise to 35ml of propan-2-ol with constant agitation at room temp	17
16mg USP Insulin (18405)	1.6ml of 0.01MHCl	9.1	0.44	1.6ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	2.8ml of insulin in DL- valine added dropwise to 28ml of propan-2-ol with constant agitation at room temp	17
12mg USP Insulin (18405)	1.2ml of 0.01MHCl and then 60µl of 1M NaOH added	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	2.1ml of insulin in DL- valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp	17
12mg USP Insulin (18405)	1.2ml of 0.01MHCl and then 60µl of 1M NaOH added	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	2.1ml of insulin in DL- valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp	17
12mg USP Insulin (18405)	1.2ml of 0.01MHCl	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	2.1ml of insulin in DL- valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp	17

12mg USP Insulin (18405)	1.2ml of 0.01MHCl	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	2.1ml of insulin in DL- valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp	17
20mg USP Insulin (18405)	2.0ml of 0.01MHCl and then 100µl of 1M NaOH added	9.1	0.44	2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	3.5ml of insulin in DL- valine added dropwise to 35ml of propan-2-ol with constant agitation at room temp	17
17mg USP Insulin (18405)	1.7ml of 0.01MHCl and then 85µl of 1M NaOH added	9.1	0.44	1.7ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	3.4ml of insulin in DL- valine added dropwise to 34ml of propan-2-ol with constant agitation at room temp	17
17mg USP Insulin (18405)	1.7ml of 0.01MHCl and then 85µl of 1M NaOH added	9.1	0.44	1.7ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL- valine	Dry propan- 2-ol	3.4ml of insulin in DL- valine added dropwise to 34ml of propan-2-ol with constant agitation at room temp	17

These results demonstrate that the particles can be produced reproducibly.

#### Example 5

##### Particle Size Analysis

Laser diffraction particle size analysis was carried out on bioactive coated particles using a Mastersizer 2000. Briefly, enough PCMC was added to the sample holder of the Mastersizer 2000 containing 60ml of 2-propanol to ensure a laser obscuration of between 10 and 20%. Measurements were then taken using a previously set up Standard Operating Procedure.

$d(0.1) \text{ (}\mu\text{m)} = 10\%$  of the particles are below this particle size

$d(0.5) \text{ (}\mu\text{m)} = 50\%$  of the particles are above and below this particle size

$d(0.9) \text{ (}\mu\text{m)} = 90\%$  of the particles are below this particle size.

$$\text{Span} = d(0.9) - d(0.1) / d(0.5)$$

Span gives a good indication of population homogeneity. Thus, span values below 5 are preferred and span values below 2 are particularly preferred.

Typical size distribution patterns produced when saturated solutions of glycine and alanine are used as the core excipients are shown in Figures 1 and 2. Figure 1 shows the particle size distribution for insulin/glycine precipitated in propan-2-ol. Figure 2 shows  $\alpha$ -chymotrypsin/alanine precipitated in propan-2-ol.

Figures 1 and 2 demonstrate a large particle size distribution when saturated solutions or concentrated solutions of very soluble excipients (e.g. glycine and alanine) are used as the core material in the co-precipitation process carried out according to WO 0069887. In particular it can be seen that there are two populations one composed of the particles and the larger composed of agglomerates of the smaller particles. This is not desirable for the production of pharmaceutical formulations with homogeneous solubility and bioavailability properties.

In contrast Figures 3-9 show a much narrower particle size distribution is obtained when less soluble excipients such as DL-valine, L-glutamine and L-histidine make up the core of the particles. They also demonstrate that little or

no large aggregates are formed. These particles may be expected to provide pharmaceutical formulations with homogeneous solubility and bio-availability properties.

Figure 3 represents PCMCs formed when 15mg chymotrypsin was dissolved in 3ml of 50% saturated DL-valine solution. 6 ml of the aqueous solution was precipitated in 35 ml of DL-valine saturated 2-propanol. The particles were dried using Millipore filtration system.

Figure 4 represents PCMCs formed when 0.2ml of saturated DL-valine solution was precipitated in 60ml unsaturated 2-propanol using a Hamilton syringe in a Mastersizer sample chamber, with a stirrer speed = 2000rpm. Particles were formed inside the Mastersizer and were directly measured. The narrower size distribution seen in this sample is thought to arise because a high agitation speed was used and because the particles have not been isolated in the form of a dry powder. Using conventional isolation techniques typically leads to more aggregated formulations.

Figure 5 represents PCMCs formed when 14ml of saturated L-histidine is precipitated in 140ml L-histidine saturated 2-propanol using a magnetic stirrer. The particles were dried using Millipore filtration system.



Figure 6 represents PCMCs formed when 0.2ml of saturated DL-valine is precipitated in 60ml unsaturated 2-propanol in Mastersizer sample chamber, with a stirrer speed = 1500rpm. Particles were formed inside Mastersizer and were directly measured.

Figure 7 represents PCMCs formed when 0.6ml L-glutamine saturated solution is precipitated in 6ml L-glutamine saturated 2-propanol solution using 5ml pipette under fast stirring. The particles were dried using Millipore filtration system.

Figure 8 represents PCMCs formed when 0.6ml L-glutamine saturated solution is precipitated in 6ml of L-glutamine saturated 2-propanol solution using small syringe pump under fast stirring. The particles were dried using Millipore filtration system.

Figure 9 represents PCMCs formed when 5% loading albumin/L-glutamine was precipitated in propan-2-ol, medium stirring. 1mg of albumin was dissolved in 0.6ml L-glutamine saturated solution. 0.5ml of this solution was precipitated into 5ml 2-propanol saturated with L-glutamine using syringe pump under medium stirring. The particles were dried using Millipore filtration system.

Table 5 shown below summarises the results shown in Figures 1 to 9.

Table 5

Formulation	d(0.1) $\mu\text{m}$ (SD)	d(0.5) $\mu\text{m}$ (SD)	D(0.9) $\mu\text{m}$ (SD)	Span (SD)
Figure 1	5.719 (0.062)	19.790 (0.557)	317.870 (8.207)	15.777 (0.146)
Figure 2	4.779 (0.092)	17.995 (1.567)	137.383 (9.808)	7.720 (0.139)
Figure 3	10.823 (0.163)	22.243 (0.343)	42.241 (0.191)	1.412 (0.012)
Figure 4	6.869 (0.097)	10.662 (0.168)	16.162 (0.268)	0.871 (0.003)
Figure 5	4.917 (0.105)	9.940 (0.147)	21.156 (1.085)	1.431 (0.228)
Figure 6	5.965 (0.076)	9.002 (0.125)	13.321 (0.197)	0.815 (0.005)
Figure 7	11.914 (0.057)	23.227 (0.144)	42.006 (0.400)	1.292 (0.002)
Figure 8	9.615 (0.160)	20.046 (0.245)	37.665 (0.462)	1.399 (0.001)
Figure 9	13.485 (0.190)	26.281 (0.317)	48.044 (0.567)	1.314 (0.003)

d(0.1), d(0.5), d(0.9) and span mean values and standard deviation (n=3).

The results in Table 5 show that formulations with a relatively narrow size distributions and which exhibit minimal aggregation can be reproducibly obtained by selecting preferred coprecipitants. It can also be seen that the mean mass diameter of these particles as determined by the mastersizer is typically less than 30 microns and may be less than 10 microns. SEM images of the particles typically demonstrate that the mean maximum

cross-sectional dimensions is qualitatively lower than the mean mass dimension measured by the Mastersizer.

### Example 6

#### Dose Emissions from Dry Powder Inhalers

Dose emissions from dry powder inhalers were determined using an Astra Draco Multi-Stage Liquid Impinger (MSLI). A useful part of the dose is called the Fine Particle Fraction (FPF). The Fine Particle Fraction (FPF) is generally collected on the lower Stages of the MSLI as shown in Table 6 below. Table 6 was used to work out the cut-off dimension of the important Stages.

Table 6

Stage	Cut-off dimension ( $\mu\text{m}$ )	Flow rate ( $\text{l min}^{-1}$ )
Stage 4	$\text{ECD}_4 = 1.7 (Q/60)^{1/2}$	$30 \leq Q \leq 100$
Stage 3	$\text{ECD}_3 = 3.1 (Q/60)^{1/2}$	$30 \leq Q \leq 100$
Stage 2	$\text{ECD}_2 = 6.8 (Q/60)^{1/2}$	$30 \leq Q \leq 100$

In the following experiments a flow rate (Q) of  $60 \text{ l min}^{-1}$  was used, giving the following cut-off dimensions of Stages 2, 3 & 4 of  $6.8$ ,  $3.1$  and  $1.7\mu\text{m}$ , respectively.

The following procedure was used in all MSLI experiments:

(a) for initial work on commercially available salbutamol sulphate formulations (e.g. Ventolin) the formulations were used as received.

(b) for PCMC formulations Size 3 capsules were filled with an amount of dry powder PCMC commonly between 10-20mg.

(c) a filter paper was added to Stage 5 of the MSLI prior to clamping of Stages 1 to 4. To each of Stages 1 to 4 was added 20ml of water. After attaching the neck section to the top of Stage 1, the adaptor piece was attached to the end of the neck. Use of the dry powder inhaler was initiated by piercing holes in either the blister pack in the case of the diskhaler or Size 3 capsules in the case of the aerohaler. The dry powder inhaler was subsequently housed in the adaptor and the pump was switched on for 4 seconds to deliver the formulation from the inhaler to the MSLI. An actuation was carried out for each blister or capsule inside the inhaler.

In every case, PCMC formulation dose emissions were delivered to the MSLI using the aerohaler.

After delivery of the formulation to the MSLI sample collection was carried out as follows:

(a) the device was removed from the adaptor and the capsules removed and placed in a petri dish followed by the addition of 20ml of water.

(b) the adaptor was removed from the neck of the MSLI and placed in a petri dish followed by the addition of 10ml of water.

(c) the neck was removed from the MSLI and rinsed out with 20ml water into a petri dish.

(d) Stages 1 to 4 were unclamped from the filter stage and the opening of Stage 1 was rinsed with 20ml of water. This was followed by agitation to dissolve all powder.

(e) the filter was removed from the MSLI and placed in a petri dish followed by the addition of 10ml of water.

(f) 5 ml aliquots were removed from each Stage and assayed by HPLC to determine salbutamol sulphate concentration. A Bio Rad Protein microassay was used to determine PCMC protein concentration.

#### Initial Work using Salbutamol Sulphate Formulations

Results of Salbutamol sulphate emissions from the Diskhaler (Tables 7 and 8) and the Aerohaler (Inhalator) (Tables 9 and 10) are shown below.

Table 7- Diskhaler

Stage	% recovered of total emitted dose
Device and blister pack	12.6
Neck and adaptor	14.3
Stage 1	41.9
Stage 2	6.9
Stage 3	7.5
Stage 4	9.1
Stage 5	7.9

FPF = 25%

Total drug amount recovered of dose claim 98%

Table 8 - Diskhaler

Stage	% recovered of total emitted dose
Device and blister pack	12.9
Neck and adaptor	17.1
Stage 1	37.8
Stage 2	6.7
Stage 3	8.3
Stage 4	9.4
Stage 5	7.8

Fine Particle Fraction (Stages 3,4 & 5) = 26%

Total drug amount recovered of dose claim 92%

Table 9 - Aerohaler

Stage	% recovered of total emitted dose
Device and blister pack	11.3
Neck and adaptor	25.2
Stage 1	33.4

65

Stage 2	7.2
Stage 3	8.7
Stage 4	8.3
Stage 5	5.9

Fine Particle Fraction (Stages 3,4 & 5) = 23%

Total drug amount recovered of dose claim 92%

Table 10 - Aerohaler

Stage	% recovered of total emitted dose
Device and blister pack	11.0
Neck and adaptor	24.1
Stage 1	33.1
Stage 2	9.0
Stage 3	8.5
Stage 4	8.6
Stage 5	5.7

Fine Particle Fraction (Stages 3,4 & 5) = 23%

The Ventolin Diskahler provided a Fine Particle Fraction (FPF) of almost 26% in the MSLI. About 70% of the dose from the ventolin diskhaler was delivered to the impactor. The Inhalator (Atrovent) provided a Fine Particle Fraction (FPF) of about 28% in the MSLI.

These values correspond to those reported in the literature for such formulations and devices and demonstrate that the MSLI was calibrated and operating correctly.

PCMC Dose Emissions in the MSLI

## CHYMOTRYPSIN FORMULATIONS

Chymotrypsin PCMCs were produced using the following technique:

Chymotrypsin was dissolved in saturated amino acid solutions to give an aqueous solution with a concentration of 10mg/ml. The aqueous solution was precipitated in a volume of 2-propanol pre-saturated with an appropriate amino acid (e.g. L-glycine, L-alanine, DL-valine, DL-serine, L-leucine and DL-isoleucine) 15 times that of the aqueous solution.

Table 11 - Chymotrypsin/L-glycine

Stage	% recovered of total emitted dose
Stage 1	54.4
Stage 2	5.6
Stage 3	1.5
Stage 4	2.5
Stage 5	0.9
Neck	10.4
Adaptor	4.8
device and capsules	19.8

FPF= 5.0%

Table 12 - Chymotrypsin/L-alanine

Stage	% recovered of total emitted dose
Stage 1	47.6
Stage 2	7.8
Stage 3	5.4
Stage 4	1.5



67

Stage 5	1.4
Neck	2.7
Adaptor	0.7
device and capsules	32.8

FPF = 8.4%

Table 13 - Chymotrypsin/DL-valine

Stage	% recovered of total emitted dose
Stage 1	37.5
Stage 2	13.4
Stage 3	11.4
Stage 4	4.5
Stage 5	6.2
Neck	15.5
Adaptor	3.3
device and capsules	8.2

FPF = 22.1%

Table 14 - chymotrypsin / DL-serine

Stage	% recovered of total emitted dose
Stage 1	63.0
Stage 2	6.4
Stage 3	6.8
Stage 4	6.9
Stage 5	1.7
Neck	5.3
Adaptor	2.8
device and capsules	6.9

FPF = 15.4%

Table 15 - Chymotrypsin / L-Leucine

Stage	% recovered of total emitted dose
Stage 1	73.3
Stage 2	9.6
Stage 3	0.4
Stage 4	0.7

Stage 5	0.3
Neck	7.9
Adaptor	3.5
device and capsules	2.4

FPF = 1.4%

Table 16 - Chymotrypsin / DL-isoleucine .

Stage	% recovered of total emitted dose
Stage 1	47.4
Stage 2	11.3
Stage 3	9.8
Stage 4	5.7
Stage 5	1.1
Neck	14.7
Adaptor	4.9
device and capsules	5.2

FPF = 16.6%

These results demonstrate that higher fine-particle fractions tend to be obtained using crystalline core materials with an aqueous solubility at 25 centigrade in the range 20 mg/ml to 80 mg/ml. Leucine shows a much lower fine particle fraction but nevertheless produces a relatively high emitted dose. The high emitted dose is an indication of the free flowing nature of this and the other preferred amino-acids.

#### INSULIN FORMULATIONS

Insulin PCMCs were then prepared in a similar fashion to the chymotrypsin PCMCs.

Table 17 - insulin/L-glycine

Stage	% recovered of total emitted dose
Stage 1	64.2
Stage 2	2.4
Stage 3	4.3
Stage 4	2.6
Stage 5	0.3
Neck	6.6
Adaptor	0.8
device and capsules	18.7

FPF = 7.2%

Table 18 - insulin/L-alanine

Stage	% recovered of total emitted dose
Stage 1	66.8
Stage 2	7.7
Stage 3	7.5
Stage 4	2.4
Stage 5	0.6
Neck	5.0
Adaptor	3.2
device and capsules	7.1

FPF = 10.5%

Table 19 - insulin/DL-valine

Stage	% recovered of total emitted dose
Stage 1	29.5

70

Stage 2	11.7
Stage 3	20.0
Stage 4	14.2
Stage 5	5.8
Neck	8.6
Adaptor	3.4
device and capsules	6.9

FPF = 40.0%

Table 20 - insulin/Na-glutamate

Stage	% recovered of total emitted dose
Stage 1	30.3
Stage 2	10.5
Stage 3	15.2
Stage 4	10.5
Stage 5	4.9
Neck	15.2
Adaptor	4.4
device and capsules	9.0

FPF = 30.6%

Table 21 - insulin/L-arginine

Stage	% recovered of total emitted dose
Stage 1	53.9
Stage 2	28.1
Stage 3	0.5
Stage 4	0.2
Stage 5	0.4
Neck	13.9
Adaptor	1.3
device and capsules	1.9

FPF = 1.1%

Table 22 - insulin/L-val

Stage	% recovered of total emitted dose
Stage 1	48.3
Stage 2	11.6
Stage 3	10.4
Stage 4	9.6
Stage 5	3.0
Neck	11.9
Adaptor	1.6
device and capsules	3.6

FPF = 23.0%

Table 23 - insulin/L-histidine

Stage	% recovered of total emitted dose
Stage 1	26.6
Stage 2	19.0
Stage 3	20.6
Stage 4	5.6
Stage 5	4.0
Neck	7.8
Adaptor	5.5
device and capsules	11.0

FPF = 8.4%

These results also demonstrate that higher fine-particle fractions and free flowing powders tend to be obtained using crystalline core materials with an aqueous solubility at 25 centigrade in the range 20 mg/ml to 80 mg/ml. Na glutamate shows a higher fine particle fraction than expected but this is thought to arise from poor coating of the protein onto the particles resulting in the

formation of separate protein particles. This is substantiated by the poorer emitted dose for this formulation due to aggregate formation.

#### ALBUMIN FORMULATIONS

75mg albumin was dissolved in a 15ml saturated solution of L-glutamine and dispensed by a syringe pump into 150ml 2-propanol in a dissolution vessel at 500 rpm.

Table 24 - insulin/L-glutamine

Stage	% recovered of total emitted dose
Stage 1	46.0
Stage 2	8.3
Stage 3	12.8
Stage 4	12.5
Stage 5	3.8
Neck	7.1
Adaptor	2.9
device and capsules	6.6

FPF = 29.1%.

Together these results back up the suggestion from the Mastersizer experiments that using concentrated solutions of very soluble excipients for the core material (e.g. glycine, alanine, arginine) results in bioactive molecule coated particles that are unsuitable for pharmaceutical formulations and in particular pulmonary drug delivery due to aggregation. It can be seen on the other hand that

particles made with less soluble amino acids (e.g. histidine, glutamine and valine) produce free flowing powders. These may be used to provide formulations suited for pulmonary drug delivery. It is further anticipated that improvements to the production process may be used to provide particles with even higher fine particle fractions.

#### Example 7

#### Controlled Release Experiments

Poly-Lactic acid (PLA) coated albumin/L-glutamine PCMCs were used in controlled release experiments.

The following method was carried out to coat albumin/L-glutamine PCMCs with PLA. The albumin/L-glutamine PCMCs were prepared by dissolving 31mg of albumin in 6.2ml of 50% saturated L-glutamine solution. The aqueous solution was then precipitated in 40ml of L-glutamine saturated 2-propanol. The particles were dried using Millipore filtration system. The albumin/L-glutamine PCMCs were coated as follows:

Expt A: 20mg albumin/L-glutamine PCMCs were suspended in 2ml acetone/PLA solution (50mg/ml) followed by evaporation of acetone. The resultant formulation formed a

very thick PLA solution that upon complete drying formed a very sticky, brittle precipitate.

Expt B: 20mg albumin/L-glutamine PCMCs were suspended in 2ml acetone/PLA solution (50mg/ml) and precipitated in 20ml 2-propanol under vigorous stirring. The resultant formulation formed a large insoluble pellet.

Expt C: 10mg albumin/L-glutamine PCMCs were suspended in 10ml 2-propanol followed by the addition of 0.4ml acetone/PLA solution (50mg/ml) under vigorous stirring.

Protein release studies were performed on the dried coated PCMCs as follows:

The coated PCMCs were added to 15ml of H<sub>2</sub>O and agitated. At defined time intervals 0.8ml aliquots of the aqueous solutions were added to 0.2ml of Bio Rad Protein microassay and assayed by UV at 595nm to determine the amount of protein released. The protein release from an uncoated PCMC control was also determined. The results of this study are shown in Table 25 below.

Table 25

time (min)	% protein released			
	uncoated PCMC	coated PCMC C	coated PCMC A	coated PCMC B
1	100	13.0	3.1	0.4
40	100	27.2	11.9	2.8
90	100	44.2	14.1	5.5
180	100	57.7	20.1	10.6



270	100	69.6	23.9	14.0
360	100	68.9	25.4	15.6

From Table 25 it is clear that the PLA coating afforded a sustained release profile compared to the uncoated PCMCs which were released into the aqueous solution within 1 min. By altering the coating it is also possible to modify release of the protein. It is therefore possible to customise the release of a protein from a PCMC for a specific use.

#### Example 8

##### Dynamic Vapour Sorption (DVS)

The uptake of water by bioactive molecule coated particles produced by the present co-precipitation process and of the core material precipitated alone under a controlled humidified environment was carried out by Dynamic Vapour Sorption (DVS) using Dynamic Vapour Sorption 1000 (Surface Measurement Systems).

The Experimental set-up was as follows.

The DVS used a 2 full-cycle experimental Special Automatic Operation (SAO) protocol that included an initial drying stage at 0% Relative Humidity (RH). This was followed by a sorption stage where the RH in each stage had an incremental increase of 10% up to 90% RH and then a

final jump to 95% RH. This was proceeded by an identical desorption cycle down to 0% RH. This cycle was repeated. The following criteria was used to control the DVS stage change: either the rate of change of the increase in mass i.e.  $dm/dt$  dropped to 0.002, or the maximum stage time was 2000 minutes.

Prior to introduction of the sample, the balance was tared and the instrument was allowed to equilibrate until a stable baseline was observed. The particles were then loaded and the initial weight recorded, followed by switching on the SAO. The experiment ran until the completion of the SAO.

Figures 10 to 14 are DVS graphs of L-glutamine; L-glycine; L-glycine/insulin PCMCs; DL-valine/insulin PCMCs; and DL-valine, respectively.

Figures 10 to 14 show that the core coprecipitants exhibit very low hygroscopicity at relative humidities up to 80%. Above 80% RH more soluble coprecipitants like L-glycine (Figure 11) start to take up appreciable amounts of water. It is found that the coating of protein on the surface of the core material results in a formulation that takes up more water than the core material alone. This is expected because the protein is coated on the outside of

the crystals. Importantly the samples typically exhibit minimal changes to their vapour sorption isotherm after passing through a complete cycle. i.e. the second sorption cycle is generally very similar to the first. Those skilled in the art will recognise that this illustrates that the particles do not undergo significant water vapour induced changes such as glass to crystalline transitions. The particles are therefore expected to be stable to storage at high humidity.

In another experiment a single cycle SAO (SAO2) was used that ramped the relative humidity from 0% to 80% after an initial drying phase, followed by an identical desorption stage. This is shown in Figure 15. The sample was collected and ran in the MSLI following the procedure previously described (MSLI section).

75mg albumin was dissolved in a 15ml saturated solution of L-glutamine and dispensed by a syringe pump into 150ml 2-propanol in a dissolution vessel at 500 rpm. 10mg of the dry powder formulation was ran in the MSLI before and after hydration in the DVS using SAO2.

Table 26 shows before incubation in the DVS

Table 26

Stage	% recovered of total emitted dose
Stage 1	46.0
Stage 2	8.3
Stage 3	12.8
Stage 4	12.5
Stage 5	3.8
Neck	7.1
Adaptor	2.9
device and capsules	6.6

FPF = 29.1%.

Table 27 shows after incubation in the DVS

Table 27

Stage	% recovered of total emitted dose
Stage 1	48.0
Stage 2	8.8
Stage 3	13.5
Stage 4	14.9
Stage 5	3.5
Neck	7.8
Adaptor	1.9
device and capsules	1.4

FPF = 31.9%

The results shown in Tables 26 and 27 demonstrate that the free flowing nature, fine particle fraction and degree of aggregation of the particles is substantially unaffected

by incubation at 80% RH in the DVS. This has important benefits for the production of pharmaceutical formulations and in particular pulmonary formulations since exposure to a humid atmosphere may occur in a delivery device.

### Example 9

#### Production of PCMCs in a Flow Precipitator

Figure 16 is a representation of a continuous flow precipitation apparatus, generally designated 10. The flow precipitation apparatus 10 comprises a source of solvent A 12 (e.g. aqueous solution containing the concentrated co-precipitant and bio-active molecules) and solvent B 14 (e.g. co-precipitant saturated solvent phase). The solvents 12, 14 are pumped by pumps (not shown) along biocompatible tubing 16 to a mixing device 18. A cross-section of the mixing device 18 is also shown which shows the solvents 12, 14 entering the mixing device 18 and an exit port and discharge pipe 20. A suspension collection vessel 22 is used to collect the formed PCMCs.

One pump continuously delivers the aqueous solution containing the concentrated coprecipitant and bioactive molecule while the other pump delivers the coprecipitant saturated solvent phase. Further pumps may be used if a

third component such as a particle coating material is required.

The pumps can be of many different kinds but must accurately deliver the solutions at a defined flow rate and be compatible with the bioactive molecules employed. Conveniently, HPLC pumps can be used since these are optimised for delivering aqueous solutions and water miscible solvents over a range of flow rates. Typically, the aqueous solution will be delivered at flow rates between 0.1 ml/min and 20 ml/min. The aqueous pump head and lines should be made of material that resist fouling by the bioactive molecule. The solvent is generally delivered 4-100 times faster than the aqueous and so a more powerful pump may be required. Typically the solvent will be delivered at between 2 ml/min and 200 ml/min.

The mixing device 18 provides a method for rapidly and intimately admixing a continuous aqueous stream with a continuous water miscible solvent stream such that precipitation begins to occur almost immediately. The diagram in Figure 16 is for illustrative purposes only and many different geometries could be employed.

The mixing device 18 may be any device that achieves rapid mixing of the two flows. Thus it can, for example, be

a static device that operates by shaping the incoming liquid flow patterns or else a dynamic device that actively agitates the two solvents streams together. Preferably, it is a dynamic device. Agitation of the two streams can be achieved by use of a variety of means such as stirring, sonication, shaking or the like. Methods of stirring include a paddle stirrer, a screw and a magnetic stirrer. If magnetic stirring is used a variety of stirring bars can be used with different profiles such as for example a simple rod or a Maltese cross. The material lining the interior of the mixing device should preferably be chosen to prevent significant binding of the bioactive molecule or the particles onto it. Suitable materials may include 316 stainless steel, titanium, silicone and Teflon (Registered Trade Mark).

Depending on the production scale required the mixing device may be produced in different sizes and geometries. The size of the mixing chamber required is a function of the rate of flow of the two solvent streams. For flow rates of about 0.025 - 2 ml/min of aqueous and 2.5-20 ml/min of solvent it is convenient to use a small mixing chamber such as 0.2ml.

## Experimental Protocol

### Continuous Flow Co-precipitator

A continuous co-precipitation system was developed using two HPLC pumps and a re-designed dynamic solvent mixing chamber. The pumps used were Gilson 303 HPLC pumps which allow variable flow rates from 0.01-9.99ml min<sup>-1</sup>. The re-designed mixing chamber, previously a Gilson 811 C dynamic mixer, was modified to allow rapid mixing and crystallisation of co-precipitants. The aim of the design was to produce a flow cell with a low internal dwell volume that allowed rapid discharge of the product crystals.

The internal static mixer/filter element was removed from a Gilson 811 C mixing chamber and replaced by a custom made insert machined from PTFE. This insert was designed to provide a much reduced internal dwell volume and to increase the internal flow turbulence. Increased turbulence is expected to reduce both crystal size and minimise cementing of crystals to form aggregates. The internal turbulence was also further controlled by modifying the internal dynamic mixer. The original element was replaced with an alternate magnetic stirring bar, shaped like a Maltese cross and this was then coupled to a variable speed



MINI MR standard magnetic stirrer module, which allowed speeds from 0-1500 rpm to be attained.

The discharge tube had an internal dimension of approximately 0.5 mm and was linked to a sealed glass jar in which the suspension was continuously collected and allowed to settle.

Continuous Flow Micro-crystal Precipitation of  
Pharmacologically Useful Materials

A saturated solution of the material of interest was prepared in a mainly aqueous solution that may if required contain some water miscible solvent. A saturated solution of the same material was prepared in a mainly water miscible solvent or mixture of solvents. The mainly aqueous solution is delivered by one pump into the dynamic mixer and the mainly solvent solution is delivered by another pump. The flow rates of the two pumps can be tuned to provide the most appropriate conditions for precipitation to occur. In general the flow rate of one pump will be at least 4 times greater than the other in order for the change in solvent conditions to be sufficiently rapid that precipitation begins to take place within the mixing

chamber. In other words nucleation needs to be rapid in order for microcrystals (i.e. PCMCs) to form.

**Example: D,L- Valine microcrystals**

The basic procedure starts by saturating the two selected solvents with DL-valine. In this particular example, the two solvents were water and isopropanol. Water was obtained in-house from Millipore water purification system. Isopropanol (Propan-2-ol/GPR) Product No 296942D, Lot No K30897546 227, was supplied by BDH and D,L-Valine, Product No. 94640, Lot No. 410496/1 was supplied by Fluka Chemik. Both solutions were saturated by placing an excess of DL-valine into a specified amount of solvent. This was then shaken overnight on an automatic shaking machine. After approximately 12 hours shaking at room temperature, solvents were filtered, through Whatman Durapore (0.45 $\mu$ m) membrane filters.

Following solution preparation, pump A was primed with the protein/DL-valine aqueous solution. Pump B was primed with DL-valine solution. Prior to beginning co-precipitation, magnetic stirrer speed was set at ~750 rpm. Pump A was set at 0.25 ml min<sup>-1</sup>, pump B was set at 4.75 ml

min<sup>-1</sup>. Once prepared, pumps were simultaneously started, thus beginning co-precipitation.

Isolation of the micro-crystals (i.e. PCMCs) by gravity filtration and agitation produced free flowing dry powders. SEM images of the crystals show a narrow size dispersion and a consistent plate-like morphology.

#### L-glutamine microcrystals

The basic procedure starts by saturating the two selected solvents with L-glutamine. In this particular example, the two solvents were water and isopropanol. Water was obtained in-house from Millipore water purification system. Isopropanol (Propan-2-ol/GPR) Product No 296942D, Lot No K30897546 227, was supplied by BDH and D,L-Valine, Product No. 94640, Lot No. 410496/1, supplied by Fluka Chemika. Both solutions were saturated by placing an excess of L-glutamine into a specified amount of solvent. This was then shaken overnight on an automatic shaking machine. After approximately 12 hours shaking at room temperature, solvents were filtered, through Whatman Durapore (0.45µm) membrane filters.

Following solution preparation, pump A was primed with the aqueous L-glutamine solution. Pump B was primed with

the isopropanol L-glutamine solution. Prior to beginning co-precipitation, magnetic stirrer speed was set at ~750 rpm. Pump A was set at  $0.25 \text{ ml min}^{-1}$  and pump B was set at  $4.75 \text{ ml min}^{-1}$ . Once prepared, pumps were simultaneously started, thus initiating the continuous flow co-precipitation process.

Isolation of the micro-crystals by gravity filtration produced compacted dry powder. SEM images of the crystals show a narrow size dispersion and a consistent elongated plate-like morphology

A similar procedure was also used to precipitate glycine from saturated solution.

#### Bioactive molecule Micro-crystal Co-precipitation (i.e. Formation of PCMCs)

Below describes a typical co-precipitation experiment, the principle of which was obtained from previous milligram batch preparations of protein coated microcrystals.

As a test platform, the protein Europa esterase 1 (Cc/F5), isolated from *Candida cyclindracea (rugosa)* Product No. EU122C, Lot No. LAY Y53-002, supplied by Europa Bioproducts Ltd. was precipitated on to D,L-Valine, Product No. 94640, Lot No. 410496/1, supplied by Fluka Chemika. The

co-precipitated product was then isolated by filtration, whereupon it was analysed by scanning electron microscopy and enzymatic assay.

The basic procedure starts by saturating two solvent solutions with DL-valine. In this particular example, these two solutions were water and isopropanol. Water was obtained in-house from Millipore water purification system. Isopropanol (Propan-2-ol/GPR) Product No 296942D, Lot No K30897546 227, was supplied by BDH. Both solutions were saturated by loading in an excess of DL-valine into a specified amount of solvent. This was then shaken overnight on an automatic shaking machine. After approximately 12 hours shaking at room temperature, solvents were filtered, through Whatman Durapore (0.45 $\mu$ m) membrane filters.

To the filtered, saturated water solution was then added a prescribed amount of esterase protein, made up in buffer.

Following solution preparation, pump A was primed with the protein/DL-valine aqueous solution. Pump B was primed with DL-valine solution. Prior to beginning co-precipitation, magnetic stirrer speed was set at ~750 rpm. Pump A was set at 0.25 ml min<sup>-1</sup>, pump B was set at 4.75 ml

min<sup>-1</sup>. Once prepared, pumps were simultaneously started, thus being co-precipitation.

Co-precipitated crystal products (i.e. PCMCs) were collected in a flask, and allowed to settle overnight. After settling, 90% of supernatant solution was decanted off. The flask was refilled with fresh isopropanol, thus washing the product of excess DL-valine. After washing, product was filtered again using Whatman Durapore (0.45µm) membrane filter.

#### Analysis Procedure

After isolation of the co-precipitated crystals, characterisation of crystals was performed using optical light microscopy and scanning electron microscopy. Both techniques allowed size and shape determination of the crystals produced.

Assessing the activity of the protein post-co-precipitation was achieved by enzymatic assay. A specific assay was used, whereby the esterase protein enzyme catalyses the breakdown of p-nitrophenyl butyrate to butanol and p-nitrophenol.

Parallel studies between pure esterase supplied by Europa, and esterase co-precipitated onto DL-valine

crystals demonstrated that a substantial amount of activity had been retained.

The solvent may be removed from precipitated microcrystals. Suspensions produced by the above continuous flow system or the batch process described previously can be settled under gravity and excess solvent decanted to give a final suspension of around 5-20 % by weight. These can be further concentrated and/or dried by standard separation techniques such as filtration, centrifugation or fluidised bed.

For very low residual solvent, low bulk density pharmaceutical formulations and pharmaceutically useful materials the solvent can be removed from the above suspensions by critical point drying using supercritical CO<sub>2</sub>. This technique is known to be useful for removing residual low levels of solvent from particles. We have discovered that surprisingly it also has the advantage that it may lead to powders and pharmaceutical formulations with much lower bulk density than obtained by other isolation techniques. Low bulk density formulations are particularly useful for pulmonary delivery of bioactive molecules. Critical point drying can be carried out in a number of ways known in the art.

Example

25 ml of a 2.5 % w/v suspension of D,L-valine crystals in isopropanol (prepared as above) were loaded into a high pressure chamber and supercritical fluid CO<sub>2</sub> was flowed through the suspension until all the isopropanol was removed. The pressure was slowly released and the low residual solvent, low bulk density powder was transferred into a sealed container. The supercritical fluid drying process does not effect the narrow size dispersion.

Example 10DNA Coated Micro-crystals**Types of DNA tested:**

- Synthetic oligonucleotide DQA-HEX (Dept of Chemistry, Strathclyde University, UK)

5'HEX (T\*C)<sub>6</sub> GTG CTG CAG GTG TAA ACT TGT ACC AG

HEX = 2,5,'2',4',5',7'-hexachloro-6-carboxyfluorescein

T\* = 5-(3-aminopropynyl)-2'-deoxyuridine



Medical application: allele-specific oligonucleotide commonly used to investigate chromosome 6 in the HLA-DQ region, which encodes for the class II major histocompatibility antigens, the human leucocyte antigens, which are concerned with the immune response (D. Graham, B.J. Mallinder, D. Whitcombe, N.D Watson, and W.E Smith. Anal. Chem. 2002, 74, 1069-1074).

Distribution of DNA coated crystals in artificial lung  
(MSLI)

Oligonucleotide coated crystals have been prepared and shown to form particles suitable for pulmonary administration.

Experiments were carried out with a pure fluorescent labelled oligonucleotide DQA-Hex and a blend of this with a crude oligonucleotide preparation obtained from herring sperm. The blending experiment allowed the loading of oligonucleotide to be varied even with limited supplies of DQA-Hex.

## Methods

### 1. Preparation of OCMC

#### Sample 1: Blend of DQA-HEX and crude oligonucleotides

4.6mg crude oligonucleotides

DNA from herring sperm (Sigma D-3159, Lot 51K1281, was degraded to "crude oligonucleotides", less than 50bp, termed "crude oligos")

Add 300µl saturated D,L-valine solution, mix well and boil for 1 min, then put on ice.

Add 100µl DQA-Hex (=26.3ug), boiled for 1 min (then put on ice) prior to addition.

Add this solution drop-wise (Gilson pipettor, yellow tips) into 6ml of 2-PrOH/saturated with D,L-valine, while mixing on a magnetic stirrer at 500rpm (Heidolph MR3000) at room temperature, let settle for about 30min, then filter (Durapore membrane filters, type HVLPO4700), transfer crystals into glass vial and let air-dry.

#### Sample 2: DQA-HEX only

100µl DQA-Hex (=26.3ug), boiled for 1 min (then put on ice) prior to addition add 300µl saturated D,L-valine solution, mix well.

Precipitation as above.

## 2. Distribution of Powders in artificial lung

Capsule loaded with 15.41mg powder (sample 1) or 13.52mg powder (sample 2).

## 3. Measurement of concentrations of oligonucleotides in fractions collected in artificial lung

(a) UV260nm- total amount of oligonucleotides

Perkin Elmer - Lambda 3 - UV/VIS Spectrometer, calibration standards using crude oligonucleotides.

(b) Fluorescence of fluorescence marker HEX (556/535nm) in DQA-HEX.

Perkin Elmer - LS45 Luminiscence Spectrometer, calibration standards using DQA-HEX.

## Results

Figure 17 show the distribution of the micro-crystals in the artificial lung. The fine particle fraction (FPF) was 29.9% for micro-crystals coated with a blend of DQA-HEX and crude oligos and 24.4% for micro-crystals coated with DQA-HEX only. The results show that the MSLI protocol is robust since similar results were obtained using two different techniques for determining oligonucleotide

concentration. Similarly it can be deduced that the two types of oligonucleotides were intimately mixed and are evenly distributed as a coating on the particles. It can also be seen from the high dose emission that the particles are free flowing and from the high FPF that they are useful for preparing pulmonary formulations.

#### Example 11

It is often difficult to ascertain that the bioactive molecule is coated on the surface of the particles since the coating may be very thin such as a monolayer. One method of checking if a coating has formed is to resuspend the particles back in a saturated solution of the crystalline core material. If the bioactive molecule is trapped with the matrix it will not redissolve but if it is a coating it will redissolve leaving behind uncoated crystals. This example shows that the oligonucleotides are coated on the surface of the crystals.

#### Re-dissolution Experiment

1. Production of OCMC: 2 mg crude oligonucleotides were dissolved in 50  $\mu$ l TRIS (10 mM, pH=7.8) and 150  $\mu$ l saturated aqueous solution of D,L-valine solution. This

solution was added with a Gilson pipette (yellow tips, 0-200  $\mu$ l) to 3 ml 2-PrOH saturated with D,L-valine, while stirred on a magnetic stirrer. The vial was left without stirring for at least further 30 min.

2. Aliquots of the OCMC suspensions (160 to 800  $\mu$ l) were transferred into Eppendorf vials and spun at 9000 rpm (except A7/ B7/C7, which was separated by sedimentation). The supernatant was carefully removed and the remaining crystals air-dried.

3. Re-dissolution of crystals into known amount of saturated or near saturated aqueous solutions of D,L-valine.

4. Measurement of oligonucleotide concentration in aqueous phase after re-dissolution.

(oligonucleotide standards: 10  $\mu$ g/ml:  $OD_{260nm} = 0.226$  or  $OD_{260nm} = 1$ : 44.25  $\mu$ g/ml; either dissolved into  $H_2O$  (does not dissolve very well:  $\sim 2$ mg/ml) or saturated D,L-valine solution.

Table 28 summarises the conditions and results. From samples 1 (A1/B1/C1) and 2 (A2/B2/C2), where the crystals

were completely dissolved, we get the maximum recovery rate of  $84 \pm 2 \%$ , for samples no 3, 4, 6, 7 (D,L-valine crystals not dissolved). We find a mean recovery rate of  $80 \pm 4 \%$ . From this we can conclude, that the oligonucleotides were completely dissolved in the saturated D,L-valine solution. This strongly indicates that the oligonucleotides are not in the matrix, but on the surface of the crystals. The same would apply for PCMCs.

Table 28 summarises the re-dissolution experiments and conditions.

Table 28

Samples	Saturation of D,L valine solution	Mode of re-dissolution	Comments	DNA conc by UV <sub>260nm</sub> (µg/ml)	DNA conc calculated from initial weight (µg/ml)	% DNA re-dissolved
A1/ B1/C1	Near saturated	vortex	Crystals dissolved	82	100	82
A2/ B2/C2	Near saturated	vortex	Crystals dissolved	85	100	85
B3/C3	At 40°C	Shake overnight		779	1000	78
A4/ B4/C4	At 40°C, cooled to RT	vortex		753	1000	75
A6/ B6/C6	At 40°C, cooled to RT	Shake overnight		1027	1250	82
A7/ B7/C7	At 40°C, cooled to RT	vortex		353	417	85

### Example 12

Table 29 shows a range of conditions for forming  $\alpha_1$  - antitrypsin coated  $\alpha$ -lactose microcrystals wherein cystein (Cys) and N-acetyl cystein (NA Cys) were used as additives to prevent oxidation during the co-precipitation process.

Preparation of  $\alpha_1$  - antitrypsin coated  $\alpha$ -lactose microcrystals by precipitation into propanol generally leads to complete loss of bio-activity. The results are shown in Table 29 below.

Table 29

Solvent	Antioxidant	Water (%)	Iu.mg <sup>-1</sup>	% Activity Recovered	Protein mg.ml <sup>-1</sup>	% Protein Recovered
Propan-2-ol	Cys 10mg.ml <sup>-1</sup>	0	0.93	38	11.4	100
Propan-2-ol	Cys 10mg.ml <sup>-1</sup>	1	0.6	25	11.7	100
Propan-2-ol	Cys 10mg.ml <sup>-1</sup>	10	0.5	20	4.30	38
Propan-2-ol	NA Cys 0.22 mg.ml <sup>-1</sup>	0	0.0	0	3.92	46
Propan-2-ol	NA Cys 10 mg.ml <sup>-1</sup>	0	0.008	0.32	3.45	44

Table 29 shows that cysteine and N-acetyl cystein produces  $\alpha$  - antitrypsin coated microcrystals with a higher activity than those prepared without an antioxidant.

The experimental procedures are as defined below.

#### Cystein Addition During Precipitation and Dissolution

16mg of  $\alpha 1$  - antitrypsin was dissolved in 0.4ml TRIS buffer (20mM, pH 8) containing 10 mg.ml<sup>-1</sup> cystein and added to 1.2ml of lactose-saturated TRIS buffer (20mM, pH 8) containing 10mg.ml<sup>-1</sup> cystein. 0.4ml of this solution was added dropwise to 6ml propanol containing different amounts of water. The activity and protein concentration in the final product was measured after dissolving the crystals in 0.8ml TRIS buffer containing 10mg.ml<sup>-1</sup> cysteine.

N-Acetyl Cystein Addition During Precipitation and Dissolution

10mg  $\alpha 1$  - antitrypsin was dissolved in 1ml of lactose saturated TRIS buffer (20 mM, pH 8) containing 0.22mg.ml<sup>-1</sup> N-acetyl cystein. 0.4ml of this solution was added dropwise to 6ml of propan-2-ol containing either 0.22mg.ml<sup>-1</sup> or 10mg.ml<sup>-1</sup> N-acetyl cystein. For activity and protein concentration measurements, the crystal was dissolved in 0.4ml TRIS buffer containing the same concentration of N-acetyl cystein as the precipitation mixture.

These show that the excipient such as additives or anti-oxidants may be beneficially added to the co-precipitation to improve and retain the bio-activity.



Example 13Vaccine PCMCs

PCMCs were made using ovalbumin, Diptheria Toxoid and Tetanus Toxoid with either DL-valine or L-glutamine as the core crystalline material.

Ovalbumin, Diptheria Toxoid (DT) and Tetanus Toxoid (TT)  
coated microcrystals

In all experiments half the volume of the aqueous solution was made up of the saturated amino acid solution. Ovalbumin was supplied as a powder. An appropriate amount of powder was weighed out to give a theoretical loading on the core material of 5, 10, 20 and 40%. To this either an amount of water was added to give a 50% saturated solution of the amino acid or in the cases where 2-methyl-2,4-pentanediol was also incorporated in the aqueous phase the volume of the diol added replaced an equal volume of water to keep the concentration of the amino acid constant. The co-precipitation of the protein and carrier was carried out in a volume of 2-propanol or 2-methyl-2,4-pentanediol ten times greater than the aqueous solution, giving a final percentage of H<sub>2</sub>O in the precipitating solvent of 9.1% for

aqueous solutions without the addition of diol and 6.5% where 20% diol was added to the aqueous phase.

The aqueous solution was delivered by a syringe pump to the organic solvent contained in a small vial under magnetic stirring.

Figure 18 is an image of DT PCMCs with a 10% loading. The DT PCMCs have a crystalline core of L-glutamine and are precipitated in propan-2-ol.

Mixed Diptheria Toxoid (DT), Tetanus Toxoid (TT) and Ovalbumin Coated Microcrystals

For mixed DT / TT PCMCs appropriate volumes of the DT stock solution (concentration = 19.5mg/ml) and TT stock solution (concentration = 27.5mg/ml) were added to the aqueous solution to be precipitated to give the required theoretical loading. For the ovalbumin / TT PCMCs the appropriate amount of ovalbumin was weighed out and to this was added the required volume of TT to give the required theoretical loadings. The crystals were then prepared as described above.

Table 30 - Ovalbumin

No	protein loading (%)	Conditions	crystals (mg)
1	ovalbumin (10%)	dissolved in saturated DL-valine/H <sub>2</sub> O soln (final volume = 0.7ml) prec in 2-propanol (vol = 7ml)	21
2	ovalbumin (20%)	dissolved in saturated L-glutamine/H <sub>2</sub> O soln (final volume = 0.7ml) prec in 2-propanol (vol = 7ml)	12
3	ovalbumin (10%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume = 0.7ml) prec in 2-propanol (vol = 7ml)	21
4	ovalbumin (20%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume = 0.7ml) prec in 2-propanol (vol = 7ml)	13
5	ovalbumin (10%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume = 0.7ml) prec in 2-methyl-2,4-pentanediol (vol = 7ml)	12
6	ovalbumin (20%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln + 20% 2-methyl-2,4-pentanediol (final volume = 0.7ml) prec in 2-propanol (vol = 7ml)	26

The coprecipitated ovalbumin showed no changes in structure or aggregation levels relative to ovalbumin in the initial aqueous preparation.

Table 31 - Diptheria Toxoid (DT)

No	protein loading (%)	Conditions	crystals (mg)
1	DT (10%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume = 0.7ml) prec in 2-propanol (vol = 7ml)	21
2	DT (5%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln	12

		(final volume =0.7ml) prec in 2-propanol (vol = 7ml)	
3	DT (20%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =0.7ml) prec in 2-propanol (vol = 7ml)	21
4	DT (40%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =0.7ml) prec in 2-propanol (vol = 7ml)	23
5	DT (20%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =0.7ml) prec in 2-methyl-2,4-pentanediol (vol = 7ml)	12
6	DT (20%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln + 20% 2-methyl-2,4-pentanediol (final volume =0.7ml) prec in 2 propanol (vol = 7ml)	13

Table 32 - Tetanus Toxoid (TT)

No	protein loading (%)	Conditions	crystals (mg)
1	TT (5%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	21
2	TT (20%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	21
3	TT (40%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	23
4	TT (20%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =1.0ml) prec in 2-methyl-2,4-pentanediol (vol = 10ml)	12
5	TT (10%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln + 15% 2-methyl-2,4-pentanediol (final volume =1.4ml) prec in 2propanol (vol = 14ml)	12

6	TT (10%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln + 15% 2-methyl-2,4-pentanediol (final volume =1.4ml) prec in 2propanol (vol = 14ml)	14
---	----------	--	----

Table 33 - Mixed Crystals

No	protein loading (%)	Conditions	crystals (mg)
1	DT(10%) TT(10%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	23
2	DT(10%) TT(10%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	12
3	DT(10%) TT(10%)	dissolved in saturated L-glutamine/Tris-HCl, pH 7.8 soln + 15% 2-methyl-2,4-pentanediol (final volume =1.4ml) prec in 2propanol (vol = 14ml)	13
4	DT(15%) TT(15%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	14
5	TT(10%) ovalbumin(10%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	21
6	TT(10%) ovalbumin(30%)	dissolved in saturated DL-valine/Tris-HCl, pH 7.8 soln (final volume =1.4ml) prec in 2-propanol (vol = 14ml)	26

Diphtheria Toxoid (DT) Formulation Made Up for Mouse Study

Vaccine coated microcrystals were produced with a theoretical loading of DT of 5%. L-glutamine made up the crystalline core material and 2-propanol was used as the water miscible organic solvent.

DT was supplied as an aqueous solution at a concentration of 14.5 mg / ml. 276  $\mu$ l of the DT solution was added to 2313  $\mu$ l saturated L-glutamine solution. To this was added 2037  $\mu$ l H<sub>2</sub>O and 4.5ml of the mixture was co precipitated into 45 ml of L-glutamine saturated 2-propanol under magnetic stirring. Around 80 mg of DT-glutamine crystals were recovered and 50 mg used for a vaccine trial in mice. The DT-glutamine crystals were stored at 4°C.

#### Variation of storage conditions prior to administration

Comparable samples of DT in aqueous buffer and samples of dry DT-glutamine microcrystals were stored as follows:

- incubation at 4 degrees C for 2 weeks;
- incubation at room temperature for 2 weeks;
- incubation at 37 degrees C for 2 week; and
- incubation at 45 degrees C for 2 days.

#### In vivo Immunological Experiments Using DT as Antigen

Prior to administration to mice, the incubated microcrystals were suspended in phosphate-buffered saline (PBS). 1350 microgram of crystals (50 microgram of DT) were suspended in 500 microlitres of PBS. Each mouse received 50

microlitres of the suspension (i.e. 5 microgram of DT) by intramuscular administration in the left hind leg on day 1.

Mice were bled on day 21. Mice received a booster dose of DT - same mass of DT as before, on day 29. Mice were bled again on day 42. The sera were analysed using ELISA assays.

The primary and secondary immune responses showed that samples of DT-glutamine microcrystals gave rise to antibodies (humoral immunity) whatever the storage protocol. This proves that the production process for vaccine coated microcrystals leads to good retention of DT bioactivity and that following reconstitution and intramuscular administration the DT is freely bioavailable.

All DT samples stored in aqueous buffer also gave primary and secondary immune responses except for the sample stored at 45°C which showed no bioactivity.

The presence of a primary and secondary immune response for DT-glutamine microcrystals stored at 45°C shows that formulation of DT into microcrystals has imparted significantly enhanced storage stability at elevated temperature relative to in solution.

Such enhanced stability has important advantages for distribution and administration of vaccines in hostile

environments, emergency situations and in the developing world.

It can therefore be concluded that forming PCMCs with a vaccine coating, imparts an extra amount of stability to the vaccine which makes the vaccine easier to store and transport. This may be useful in hot countries.

#### Example 14

#### Ex-vivo Measurement of Insulin Bioactivity on Insulin Coated D,L-valine Microcrystals.

##### Part 1

Insulin bioactivity assays were carried out on resistance arteries (<200µm dimension) isolated from 12 week old male Wistar rats studied in heated (37°C) and gassed (95%O<sub>2</sub>/5%CO<sub>2</sub>) physiological salt solution (PSS) to achieve a pH of 7.4. A pressure myograph which allowed luminal application of drug provided initial measures of sensitivity. In the pressure system, arteries mounted on opposing glass cannula (outer dimension 80µm) were gradually pressurised from <5mmHg to 40 mmHg over 15 mins and held for 15 mins more before starting the assay. Responses were measured using proprietary video analysis software (MyoView). The pressure myograph is able to detect



the vasodilatory effect <sup>107</sup> of insulin at very low  
concentrations ( $1 \times 10^{-10}$  M)

### Table 34 Sample Preparation

[illegible]

**Results**

Table 34 shows insulin mediated relaxation to noradrenaline precontraction (100 = 100% constriction), mean of 3 (SD), the values show no significant difference between the microcrystals and the control ( $p > 0.05$ ).

Table 35

Log M	Commercial Insulin	Insulin coated D,L-valine microcrystals
-11	100 (0)	100 (0)
-10	84 (7)	84 (14)
-9	65 (23)	68 (22)

The degree of relaxation afforded by the insulin PCMC as shown in Figure 18 is similar to that of the USP insulin formulation indicating no insulin denaturation during production or room-temperature storage of the PCMC.

**Part 2****Wire Myograph studies**

A wire myograph was then used to provide greater throughput for subsequent studies (P110 & P660, Danish MyoTech, Aarhus. In the wire system, arteries were mounted between two 40µm stainless steel wires, one connected to a micrometer, the other to a force transducer and set to a known standardised dimension to produce an optimal pharmacological response. Force production was captured by proprietary software (MyoDaq). All bioassays began with two washes of 123mM KCl, to stimulate contractile function in the arteries, followed by precontraction by exposure to a vasoconstrictor agonist, thromboxane mimetic [U44169]. The arteries were then exposed to increasing concentrations of insulin either directly into the bath (wire) or by gradual infusion directly into the lumen via a fetal microcannulae inserted to the tip of the glass mounting cannula, at a constant pressure (pressure).

## Sample preparation

The insulin used was USP bovine pancreas insulin (Sigma 18405) Mixing was always carried out by magnetic stirring

Crystals were isolated by filtering through Durapore membrane filters (0.4 microns) and were then dried in air in the fume hood

Protein loadings are based on maximum determined from yield of crystals

Table 36

Bioactive Molecule	Bioactive Molecule dissolved in Solvent	H <sub>2</sub> O% (v/v)	Conc. of Bioactive in Molecule in Solvent (mg/ml)	Addition of excipient	Wash Step	Crystallisation Process	% protein recovered	% max protein in crystal
20mg USP Insulin (18405)	2.0ml of 0.01MHCl and then 100μl of 1M NaOH added	9.1	0.44	2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL-valine	Dry propan-2-ol	3.5ml of insulin in DL-valine added dropwise to 35ml of propan-2-ol with constant agitation at room temp		17
<b>The particles were reconstituted at a concentration of 0.9mM protein in water</b>								
16mg USP Insulin (18405)	1.6ml of 0.01MHCl	9.1	0.44	1.6ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL-valine	Dry propan-2-ol	2.8ml of insulin in DL-valine added dropwise to 28ml of propan-2-ol with constant agitation at room temp		17
<b>The particles were reconstituted at a concentration of 1mM protein in water</b>								
12mg USP Insulin (18405)	1.2ml of 0.01MHCl and then 60μl of 1M NaOH added	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL-valine	Dry propan-2-ol	2.1ml of insulin in DL-valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp		17
12mg USP Insulin (18405)	1.2ml of 0.01MHCl and then 60μl of 1M NaOH added	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL-valine	Dry propan-2-ol	2.1ml of insulin in DL-valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp		17

The particles were reconstituted at a concentration of 0.9mM protein in water

12mg USP Insulin (18405)	1.2ml of 0.01M HCl	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL-valine	Dry propan-2-ol	2.1ml of insulin in DL-valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp	17
12mg USP Insulin (18405)	1.2ml of 0.01M HCl	9.1	0.44	1.2ml of distilled water saturated with DL-valine added to insulin giving a 49% saturation of DL-valine	Dry propan-2-ol	2.1ml of insulin in DL-valine added dropwise to 21ml of propan-2-ol with constant agitation at room temp	17

The particles were reconstituted at a concentration of 0.9mM protein in water

## Results

Figure 19 shows a summary of the myograph results.

Following precontraction with thromboxane mimetic [U44169] the insulin-mediated vasorelaxation profile is  
5 typical for insulin and exerts its effect mainly via the activation of nitric oxide synthase and the subsequent release of endothelial nitric oxide.

The insulin mediated vasorelaxation afforded by the insulin coated D,L-valine microcrystals was essentially  
10 identical to the USP monomeric insulin formulation. D,L-valine on it's own showed no bioactivity. These results show that the insulin bioactivity is unchanged either by the co-precipitation process or by long-term room-temperature storage of the insulin coated microcrystals.  
15 This is strong proof that the insulin has not been chemically modified, aggregated or undergone any irreversible denaturation during processing or storage. The absence of degradation was backed up by HPLC analysis that showed that immediately following reconstitution of  
20 the D,L-valine microcrystals more than 90% of the insulin was still present in monomeric form following coprecipitation and storage as a powder at room temperature for more than 6 months. In contrast insulin retained in the same aqueous solution used for  
25 coprecipitation underwent significant aggregation in less

than 30 minutes. We have shown insulin coated D,L-valine microcrystals to be free-flowing powders which exhibit high fine-particle fractions in multi-stage impinger tests and so it is evident that bioactive molecule coated micrystals are very suitable for making pharmaceutical formulations with enhanced properties.

#### Example 15

Figures 20 to 24 are SEM images of a selection of PCMCs made according to the present invention.

Figure 20 is an SEM image of insulin/DL-valine PCMCs precipitated in propan-2-ol at X1600 magnification. Figure 21 is a further SEM image of insulin/DL-valine precipitated in propan-2-ol at X6400 magnification. Figures 20 and 21 show that the crystals are flake-like and are substantially homogeneous in shape and size and that there is a substantially even coating of insulin.

Figure 22 is an SEM image of albumin/L-glutamine PCMCs precipitated in propan-2-ol. The PCMCs in this instance are again homogeneous but are needle shaped.

Figure 23 is an SEM image of insulin/L-histidine PCMCs precipitated in propan-2-ol which are homogeneous and flake-like.

Figure 24 is an SEM image of  $\alpha$ -antitrypsin/DL-valine PCMCs precipitated in propan-2-ol. The PCMCs are shown



to be substantially homogeneous in shape and size and are  
flake-like.

1/18




Figure1. Insulin / glycine precipitated in 2-propanol




Figure2. chymotrypsin / alanine precipitated in 2-propanol

2/18




Figure 3. 15mg chymotrypsin was dissolved in 3ml of 50 %saturated DL valine solution. 6 ml of the aqueous solution was precipitated in 35 ml of DL valine saturated 2-propanol. The particles were dried using Millipore filtration system.




Figure 4. 0.2ml of saturated DL valine solution was precipitated in 60ml unsaturated 2-propanol using Hamilton syringe in mastersizer sample chamber, with a stirrer speed = 2000rpm. Particles formed inside Mastersizer and were directly measured.

3/18




Figure 5. insulin / L-histidine precipitated in 2-propanol




Figure 6. 0.2ml of saturated DL valine precipitated in 60ml unsaturated 2-propanol in mastersizer sample chamber, with a stirrer speed = 1500rpm. Particles formed inside Mastersizer and were directly measured.

4/18




Figure 7. 0.6ml L-glutamine saturated solution precipitated in 6ml L-glutamine saturated 2-propanol solution using 5ml pipette under fast stirring. The particles were dried using Millipore filtration system.




Figure 8. 0.6ml L-glutamine saturated solution precipitated in 6ml of L-glutamine saturated 2-propanol solution using small syringe pump under fast stirring. The particles were dried using Millipore filtration system.

5/18




Figure 9.5% loading albumin /L-glutamine prec in 2-prop, medium stirring  
1mg of albumin dissolved in 0.6ml L-glutamine saturated solution. 0.5ml of this solution was precipitated into 5ml 2-propanol saturated with L-glutamine using syringe pump under medium stirring. The particles were dried using Millipore filtration system.

6/18




Figure 10




Figure 11

7/18




Figure 12




Figure 13



8/18




Figure 14




Figure 15

9/18





Figure 1b

10/18



Distribution of D,L valine crystals coated with a blend of DQA-HEX and crude oligonucleotides in the artificial lung. 2-PrOH was used as precipitating solvent. Loading was 18.4% (this was calculated as weight DNA measured by  $UV_{260nm}$  per weight OCMC). The fine particle fraction (FPF) was 29.9%.

Figure 17

11/18




Figure 18